Perminder J S Bhatia, MD
Neurology · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 38 years
- Graduated 1988
Offices
2 locations · Neuro-Pain Medical Center Inc · Fresno Community Hospital and Medical Center
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center · Kaweah Health Medical Center · Saint Agnes Medical Center · San Joaquin Valley Rehabilitation Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhatia’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A61797 · Current
Licensed to practise in California · since 1997 · expires 2028-07-31 · Guru Nanak Dev University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
- Kaweah Health Medical CenterVisalia, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Kaweah Delta Health Care DistrictPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 239.86 (194.11 to 285.6) · 104 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Kaweah Health Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 3 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 239.86 (194.11 to 285.6) · 104 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.22 (0.28 to 2.16) · 1,600 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.53 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.8 · 626 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.1 · 741 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 373 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 3,927 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,045 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.38) · 9,267 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.72 (1.81 to 5.63) · 2,251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.53 to 3.61) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.45 to 3.13) · 2,231 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.88 (1.1 to 12.66) · 799 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.59 (0 to 7.19) · 759 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 416 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 0.89) · 8,159 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 43 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.728 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.405 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.023 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.551 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 344 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 799 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -17 · 286 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 31.4 · 686 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -6 · 734 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 776 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.6 to 7.6) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.9 (6.6 to 11.9) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 317 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.3 to 14) · 1,748 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 680 cases | No different | Jan 2024 – Dec 2024 |
What patients said (435 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$814,807
Medicare paid this office $814,807 for 1,561 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 935 | $178,648 | $97 |
| Measurement of brain wave activity (eeg), awake and asleep | 336 | $126,962 | $377 |
| Measurement of brain wave activity (eeg), digital analysis | 319 | $78,228 | $244 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 181 | $43,460 | $216 |
| New patient visit (45+ min) | 274 | $34,831 | $127 |
See all 28 services
| Return visit (30+ min) | 935 | $178,648 | $97 |
| Measurement of brain wave activity (eeg), awake and asleep | 336 | $126,962 | $377 |
| Measurement of brain wave activity (eeg), digital analysis | 319 | $78,228 | $244 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 181 | $43,460 | $216 |
| New patient visit (45+ min) | 274 | $34,831 | $127 |
| Short return visit (20+ min) | 343 | $31,462 | $68 |
| New patient visit (60+ min) | 146 | $25,604 | $175 |
| Muscle electrical test | 136 | $24,437 | $78 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 353 | $22,591 | $42 |
| Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | 147 | $22,400 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $14,404 | $109 |
| Nerve test | 107 | $12,360 | $110 |
| Long return visit (40+ min) | 58 | $8,925 | $144 |
| Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | 73 | $7,677 | $66 |
| Nerve test | 45 | $6,652 | $142 |
| Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | 12 | $5,927 | $22 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 17 | $5,167 | $161 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 12 | $4,065 | $113 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 23 | $2,862 | $39 |
| Measurement of brain wave activity (eeg), awake and drowsy | 64 | $2,798 | $44 |
| Evaluation of neuropsychological test, first hour | 16 | $1,651 | $103 |
| Evaluation for physical therapy, typically 30 minutes | 12 | $1,638 | $82 |
| Therapy procedure for walking training, each 15 minutes | 12 | $1,615 | $17 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 32 | $989 | $26 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 12 | $752 | $33 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 15 | $657 | $44 |
| Injection of drug or substance under skin or into muscle | 12 | $212 | $12 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $18 | None |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | – | – | – | – | 35 | 36 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,561 Original Medicare patients in 2024. Average age 74 · Under 65 14% · 85 and older 14% · Women 56% · Also on Medicaid 34% · Health risk score 1.58. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Diabetes 42% · Coronary heart disease 35% · Depression 33% · Dementia 32% · Chronic kidney disease 30% · Heart failure 21% · Atrial fibrillation 19% · Stroke 16% · COPD 15% · Cancer 13%.
The office billed $1,795,848, Medicare allowed $1,054,635 and paid $814,807; for 84,614 services of 57 kinds; $134,291 of it was for drugs given in the office and $680,516 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,561 | 84,614 | 74 | 1.58 | $1,795,848 | $814,807 |
| 2023 | 1,604 | 7,528 | 73 | 1.53 | $1,236,033 | $627,202 |
| 2022 | 1,541 | 6,842 | 72 | 1.51 | $1,399,775 | $536,020 |
| 2021 | 1,564 | 6,864 | 72 | 1.64 | $1,348,546 | $503,767 |
| 2020 | 1,434 | 8,067 | 71 | 1.78 | $1,108,163 | $381,320 |
| 2019 | 1,368 | 7,620 | 71 | 1.81 | $1,108,574 | $366,582 |
| 2018 | 1,244 | 5,546 | 72 | 1.80 | $959,579 | $336,326 |
| 2017 | 1,168 | 6,075 | 71 | 1.76 | $957,003 | $306,754 |
| 2016 | 1,088 | 5,618 | 69 | 1.77 | $945,017 | $321,250 |
| 2015 | 1,122 | 6,793 | 69 | 1.67 | $1,174,972 | $404,076 |
| 2014 | 1,245 | 9,080 | 68 | 1.60 | $1,150,104 | $429,351 |
| 2013 | 1,264 | 12,225 | 67 | 1.63 | $1,144,705 | $444,286 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Return visit (30+ min) | 973 | $184,316 | $98 |
| Measurement of brain wave activity (eeg), awake and asleep | 310 | $117,824 | $374 |
| Measurement of brain wave activity (eeg), digital analysis | 280 | $65,424 | $230 |
| Short return visit (20+ min) | 502 | $47,147 | $68 |
| Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | 333 | $38,772 | $62 |
| New patient visit (45+ min) | 278 | $35,895 | $129 |
| Muscle electrical test | 148 | $28,495 | $80 |
| New patient visit (60+ min) | 158 | $27,691 | $175 |
| Nerve test | 118 | $13,115 | $110 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 182 | $10,587 | $47 |
| Nerve test | 61 | $8,867 | $145 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 16 | $4,399 | $163 |
| Long return visit (40+ min) | 28 | $4,358 | $145 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $4,079 | $117 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 25 | $3,638 | $40 |
| Measurement of brain wave activity (eeg), awake and drowsy | 66 | $2,886 | $42 |
| Evaluation of neuropsychological test, first hour | 25 | $2,620 | $105 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 22 | $2,282 | $104 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 17 | $1,803 | $34 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 28 | $1,157 | $41 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 32 | $980 | $29 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 11 | $514 | $32 |
2022: 18 services
| Return visit (30+ min) | 976 | $194,115 | $99 |
| Measurement of brain wave activity (eeg), awake and asleep | 175 | $66,895 | $378 |
| New patient visit (45+ min) | 305 | $38,576 | $126 |
| Measurement of brain wave activity (eeg), digital analysis | 171 | $38,152 | $221 |
| Short return visit (20+ min) | 414 | $36,171 | $69 |
| New patient visit (60+ min) | 172 | $30,688 | $178 |
| Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | 287 | $29,189 | $65 |
| Muscle electrical test | 109 | $20,173 | $83 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 206 | $14,149 | $46 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 165 | $10,621 | $48 |
| Nerve test | 88 | $10,181 | $116 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 16 | $8,530 | $167 |
| Long return visit (40+ min) | 42 | $6,600 | $147 |
| Nerve test | 37 | $5,436 | $147 |
| Measurement of brain wave activity (eeg), awake and drowsy | 84 | $3,944 | $46 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 23 | $2,518 | $41 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 11 | $1,311 | $109 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 11 | $1,046 | $36 |
2021: 20 services
| Return visit (30+ min) | 863 | $182,894 | $104 |
| Short return visit (20+ min) | 549 | $56,184 | $69 |
| Measurement of brain wave activity (eeg), awake and asleep | 130 | $51,503 | $387 |
| New patient visit (45+ min) | 337 | $45,102 | $134 |
| New patient visit (60+ min) | 178 | $32,298 | $181 |
| Measurement of brain wave activity (eeg), digital analysis | 129 | $28,088 | $214 |
| Muscle electrical test | 128 | $22,972 | $86 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 173 | $13,231 | $32 |
| Nerve test | 96 | $11,763 | $121 |
| Nerve test | 44 | $7,057 | $160 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 15 | $5,422 | $169 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 23 | $5,371 | $234 |
| Measurement of brain wave activity (eeg), awake and drowsy | 97 | $5,052 | $46 |
| Long return visit (40+ min) | 33 | $4,876 | $148 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,561 | $157 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 22 | $3,194 | $40 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 16 | $1,685 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,656 | $110 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 11 | $1,211 | $110 |
| Measurement of brain wave activity (eeg), in coma or asleep | 17 | $861 | $48 |
2020: 19 services
| Short return visit (20+ min) | 732 | $90,252 | $59 |
| Return visit (30+ min) | 575 | $76,663 | $86 |
| Measurement of brain wave activity (eeg), awake and asleep | 101 | $38,018 | $376 |
| New patient visit (45+ min) | 287 | $37,344 | $130 |
| New patient visit (60+ min) | 163 | $27,675 | $170 |
| Muscle electrical test | 83 | $14,737 | $84 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 186 | $12,475 | $34 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 27 | $10,845 | $172 |
| Nerve test | 66 | $8,149 | $122 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 52 | $6,055 | $114 |
| Nerve test | 33 | $5,563 | $164 |
| Measurement of brain wave activity (eeg), digital analysis | 24 | $5,331 | $222 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 27 | $5,326 | $42 |
| Measurement of brain wave activity (eeg), awake and drowsy | 104 | $5,174 | $48 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 24 | $4,075 | $37 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,008 | $167 |
| Long return visit (40+ min) | 14 | $1,723 | $123 |
| Measurement of brain wave activity (eeg), in coma or asleep | 25 | $1,264 | $49 |
| Measurement of brain wave activity (eeg), awake and asleep | 16 | $777 | $49 |
2019: 21 services
| Return visit (30+ min) | 660 | $102,256 | $82 |
| Short return visit (20+ min) | 691 | $65,762 | $57 |
| New patient visit (45+ min) | 305 | $39,124 | $128 |
| Measurement of brain wave activity (eeg), awake and asleep | 80 | $29,696 | $362 |
| Muscle electrical test | 104 | $17,998 | $79 |
| Measurement of brain wave activity (eeg), digital analysis | 71 | $16,548 | $227 |
| New patient visit (60+ min) | 78 | $12,989 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 94 | $10,698 | $110 |
| Nerve test | 58 | $9,299 | $158 |
| Nerve test | 75 | $9,196 | $123 |
| Measurement of brain wave activity (eeg), awake and drowsy | 90 | $4,423 | $48 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 16 | $3,945 | $41 |
| Long return visit (40+ min) | 28 | $3,338 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,103 | $163 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 12 | $2,753 | $36 |
| Testing for presence of drug, read by direct observation | 60 | $988 | $12 |
| Electronic analysis of implanted neurostimulator generator with complex cranial nerve stimulator programming | 11 | $924 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $764 | $59 |
| Measurement of brain wave activity (eeg), in coma or asleep | 14 | $670 | $48 |
| Measurement of brain wave activity (eeg), awake and asleep | 15 | $666 | $44 |
| Electronic analysis of neurostimulator generator with simple cranial nerve stimulator programming | 12 | $606 | $29 |
2018: 18 services
| Return visit (30+ min) | 672 | $101,144 | $85 |
| Short return visit (20+ min) | 602 | $55,450 | $56 |
| New patient visit (45+ min) | 290 | $35,314 | $122 |
| Measurement of brain wave activity (eeg), awake and asleep | 77 | $27,746 | $356 |
| Measurement of brain wave activity (eeg), digital analysis | 77 | $18,681 | $239 |
| New patient visit (60+ min) | 88 | $14,044 | $160 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 12 | $12,648 | $201 |
| Muscle electrical test | 81 | $12,616 | $77 |
| Nerve test | 69 | $8,735 | $127 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 67 | $7,610 | $110 |
| Electronic analysis and programming of implanted complex cranial neurostimulator generator system during or after surgery, first hour | 16 | $7,039 | $164 |
| Nerve test | 37 | $5,750 | $155 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,426 | $164 |
| Measurement of brain wave activity (eeg), awake and drowsy | 84 | $3,918 | $45 |
| Testing for presence of drug, read by direct observation | 131 | $2,453 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,295 | $59 |
| Measurement of brain wave activity (eeg), awake and asleep | 18 | $764 | $42 |
| Injection of drug or substance under skin or into muscle | 13 | $241 | $17 |
2017: 20 services
| Return visit (30+ min) | 622 | $90,363 | $78 |
| Short return visit (20+ min) | 539 | $54,287 | $55 |
| Measurement of brain wave activity (eeg), awake and asleep | 69 | $24,298 | $337 |
| New patient visit (45+ min) | 158 | $19,524 | $124 |
| Measurement of brain wave activity (eeg), digital analysis | 69 | $17,716 | $246 |
| Muscle electrical test | 71 | $10,682 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 94 | $10,418 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $8,540 | $155 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 14 | $8,504 | $185 |
| Testing for presence of drug, read by direct observation | 182 | $7,027 | $15 |
| Nerve test | 44 | $6,758 | $154 |
| New patient visit (60+ min) | 44 | $6,706 | $152 |
| Nerve test | 55 | $6,323 | $115 |
| Electronic analysis and programming of implanted complex cranial neurostimulator generator system during or after surgery, first hour | 12 | $4,879 | $152 |
| Measurement of brain wave activity (eeg), awake and drowsy | 99 | $4,828 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,533 | $56 |
| Long return visit (40+ min) | 19 | $2,164 | $114 |
| Measurement of brain wave activity (eeg), awake and asleep | 30 | $1,429 | $46 |
| Measurement of brain wave activity (eeg), in coma or asleep | 22 | $1,138 | $47 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 30 | $440 | $14 |
2016: 20 services
| Return visit (30+ min) | 711 | $132,511 | $79 |
| Short return visit (20+ min) | 373 | $30,484 | $54 |
| Measurement of brain wave activity (eeg), awake and asleep | 73 | $25,894 | $341 |
| Measurement of brain wave activity (eeg), digital analysis | 73 | $19,534 | $257 |
| New patient visit (45+ min) | 129 | $15,961 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $10,337 | $157 |
| Muscle electrical test | 61 | $9,097 | $73 |
| Electronic analysis and programming of implanted complex cranial neurostimulator generator system during or after surgery, first hour | 16 | $8,872 | $164 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 14 | $8,120 | $189 |
| Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (eg immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per | 218 | $7,910 | $15 |
| Nerve test | 61 | $7,053 | $116 |
| New patient visit (60+ min) | 45 | $7,001 | $156 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 52 | $5,861 | $109 |
| Nerve test | 35 | $5,450 | $151 |
| Measurement of brain wave activity (eeg), awake and drowsy | 79 | $3,841 | $46 |
| Long return visit (40+ min) | 22 | $2,551 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,133 | $56 |
| Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (eg immunoassay) read by instrument-assisted direct optical observation (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per da | 83 | $1,630 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,073 | $83 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 25 | $339 | $13 |
2015: 18 services
| Return visit (30+ min) | 670 | $97,418 | $82 |
| Short return visit (20+ min) | 616 | $77,220 | $55 |
| Measurement of brain wave activity (eeg), awake and asleep | 142 | $48,140 | $332 |
| Measurement of brain wave activity (eeg), digital analysis | 142 | $37,128 | $256 |
| New patient visit (45+ min) | 196 | $24,813 | $127 |
| Muscle electrical test | 95 | $15,267 | $74 |
| Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter | 256 | $14,271 | $19 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 13 | $13,854 | $198 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,835 | $159 |
| Electronic analysis and programming of implanted complex cranial neurostimulator generator system during or after surgery, first hour | 17 | $9,503 | $167 |
| Nerve test | 76 | $8,822 | $115 |
| New patient visit (60+ min) | 50 | $7,948 | $159 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 68 | $7,362 | $108 |
| Nerve test | 31 | $4,820 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $3,216 | $82 |
| Long return visit (40+ min) | 20 | $2,264 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,777 | $57 |
| Measurement of brain wave activity (eeg), awake and drowsy | 23 | $1,149 | $46 |
2014: 26 services
| Return visit (30+ min) | 634 | $85,700 | $82 |
| Short return visit (20+ min) | 700 | $77,606 | $54 |
| Measurement of brain wave activity (eeg), digital analysis | 102 | $40,502 | $372 |
| Measurement of brain wave activity (eeg), awake and asleep | 101 | $35,916 | $333 |
| Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 188 | $29,360 | $97 |
| New patient visit (45+ min) | 213 | $27,065 | $127 |
| Muscle electrical test | 113 | $17,854 | $76 |
| Botox | 13 | $15,492 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $13,991 | $163 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 12 | $10,201 | $200 |
| New patient visit (60+ min) | 62 | $10,183 | $164 |
| Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 13 | $8,251 | $23 |
| Nerve test | 73 | $8,202 | $109 |
| Electronic analysis and programming of implanted complex cranial neurostimulator generator system during or after surgery, first hour | 14 | $7,772 | $162 |
| Nerve test | 49 | $7,351 | $147 |
| Alcohol (ethanol) level | 189 | $4,321 | $14 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $3,654 | $111 |
| Long return visit (40+ min) | 29 | $3,177 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $2,849 | $58 |
| Measurement of brain wave activity (eeg), awake and drowsy | 59 | $2,737 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $2,264 | $84 |
| Nerve test | 11 | $2,046 | $186 |
| Creatine measurement | 188 | $1,857 | $6 |
| Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter | 45 | $875 | $19 |
| Neuropsychological testing by a computer with interpretation and report by a qualified healthcare professional | 12 | $475 | $40 |
| Psychological testing with interpretation and report by computer | 12 | $270 | $23 |
2013: 26 services
| Short return visit (20+ min) | 782 | $86,681 | $54 |
| Return visit (30+ min) | 525 | $65,398 | $84 |
| Measurement of brain wave activity (eeg), awake and asleep | 99 | $41,353 | $398 |
| Measurement of brain wave activity (eeg), digital analysis | 100 | $40,921 | $390 |
| Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 231 | $33,509 | $99 |
| New patient visit (45+ min) | 260 | $33,052 | $127 |
| Botox | 19 | $28,368 | None |
| Muscle electrical test | 101 | $14,955 | $71 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 14 | $13,307 | $202 |
| Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 18 | $11,951 | $24 |
| New patient visit (60+ min) | 58 | $9,548 | $165 |
| Nerve test | 79 | $8,953 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,349 | $159 |
| Nerve test | 40 | $6,155 | $150 |
| Electronic analysis and programming of implanted complex cranial neurostimulator generator system during or after surgery, first hour | 17 | $5,649 | $161 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $5,362 | $107 |
| Alcohol (ethanol) level | 226 | $4,890 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,502 | $56 |
| Ultrasound of both sides of head and neck blood flow | 16 | $2,381 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $1,950 | $81 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $1,890 | $111 |
| Long return visit (40+ min) | 16 | $1,863 | $116 |
| Measurement of brain wave activity (eeg), awake and drowsy | 33 | $1,467 | $44 |
| Creatine measurement | 184 | $1,404 | $6 |
| Neuropsychological testing by a computer with interpretation and report by a qualified healthcare professional | 12 | $956 | $80 |
| Psychological testing with interpretation and report by computer | 12 | $677 | $56 |
Medicaid work
$2,164 in 2024
Medicaid paid $2,164 for 668 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 296 | $741 |
| Electroencephalogram (EEG); including recording awake and drowsy | 76 | $734 |
| Principal care management services, for a single high-risk disease, with the following required elements: one complex chronic condition expected to last at least 3 months, and that places the patient at significant risk of hospitalization, acute exacerbation/decompensation, functional decline, or death, the condition requires development, monitoring, or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen and/or the management of the condition is unusually complex due to comorbidities, ongoing communication and care coordination between relevant practitioners furnishing care; first 30 minutes of clinical staff time directed by physician or other qualified health care professional, per calendar month. | 95 | $384 |
| Principal care management services, for a single high-risk disease, with the following required elements: one complex chronic condition expected to last at least 3 months, and that places the patient at significant risk of hospitalization, acute exacerbation/decompensation, functional decline, or death, the condition requires development, monitoring, or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen and/or the management of the condition is unusually complex due to comorbidities, ongoing communication and care coordination between relevant practitioners furnishing care; first 30 minutes provided personally by a physician or other qualified health care professional, per calendar month. | 46 | $305 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 123 | $0 |
| Advance Care Planning discussed and documented in the medical record, patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan (DEM) (GER, Pall Cr) | 32 | $0 |
| 2024 | 668 | 6 | 38 | $2,164 |
| 2023 | 313 | 3 | 26 | $2,088 |
| 2022 | 193 | 3 | 36 | $377 |
| 2021 | 184 | 3 | 24 | $0 |
| 2020 | 780 | 4 | 62 | $1,490 |
| 2019 | 60 | 1 | 17 | $0 |
| 2018 | 144 | 3 | 29 | $273 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 148 | $1,106 |
| Principal care management services, for a single high-risk disease, with the following required elements: one complex chronic condition expected to last at least 3 months, and that places the patient at significant risk of hospitalization, acute exacerbation/decompensation, functional decline, or death, the condition requires development, monitoring, or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen and/or the management of the condition is unusually complex due to comorbidities, ongoing communication and care coordination between relevant practitioners furnishing care; first 30 minutes provided personally by a physician or other qualified health care professional, per calendar month. | 131 | $687 |
| Electroencephalogram (EEG); including recording awake and drowsy | 34 | $296 |
2022
| Return visit (30+ min) | 44 | $308 |
| Electroencephalogram (EEG); including recording awake and drowsy | 26 | $69 |
| Principal care management services, for a single high-risk disease, with the following required elements: one complex chronic condition expected to last at least 3 months, and that places the patient at significant risk of hospitalization, acute exacerbation/decompensation, functional decline, or death, the condition requires development, monitoring, or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen and/or the management of the condition is unusually complex due to comorbidities, ongoing communication and care coordination between relevant practitioners furnishing care; first 30 minutes provided personally by a physician or other qualified health care professional, per calendar month. | 123 | $0 |
2021
| Short return visit (20+ min) | 12 | $0 |
| Return visit (30+ min) | 41 | $0 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 131 | $0 |
2020
| New patient visit (45+ min) | 32 | $1,179 |
| Short return visit (20+ min) | 466 | $180 |
| Return visit (30+ min) | 150 | $131 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 132 | $0 |
2019
| Return visit (30+ min) | 60 | $0 |
2018
| Electroencephalogram (EEG); including recording awake and drowsy | 14 | $238 |
| Return visit (30+ min) | 77 | $34 |
| Short return visit (20+ min) | 53 | $0 |
Drugs they prescribed that Part D paid
$3,831,453
Pharmacies billed $3,831,453 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (278 of 6,167) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%. Long-acting opioids: 18% of their opioid prescriptions.
5,164 generic and 985 brand-name prescriptions · $3,831,453 in drug cost · 189 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Octagam | Immune globulin | 22 | $548,042 | $24,911 |
| Gammagard Liquid | Immune globulin | 27 | $479,450 | $17,757 |
| Gamunex-C | Immune globulin | 41 | $294,398 | $7,180 |
| Ingrezza | None | 26 | $217,070 | $8,349 |
| Rexulti | None | 85 | $153,576 | $1,807 |
See all 90 drugs
| Octagam | Immune globulin | 22 | $548,042 | $24,911 |
| Gammagard Liquid | Immune globulin | 27 | $479,450 | $17,757 |
| Gamunex-C | Immune globulin | 41 | $294,398 | $7,180 |
| Ingrezza | None | 26 | $217,070 | $8,349 |
| Rexulti | None | 85 | $153,576 | $1,807 |
| Rytary | Parkinson's | 203 | $121,547 | $599 |
| Zeposia | None | 12 | $106,487 | $8,874 |
| Kesimpta | None | 12 | $105,342 | $8,779 |
| Xcopri | None | 73 | $105,261 | $1,442 |
| Botox | None | 47 | $64,248 | $1,367 |
| Memantine | None | 1,140 | $51,399 | $45 |
| Emgality | Migraine | 61 | $40,986 | $672 |
| Gocovri | None | 12 | $38,992 | $3,249 |
| Nurtec Odt | None | 19 | $33,696 | $1,773 |
| Ubrelvy | None | 19 | $33,154 | $1,745 |
| Privigen | Immune globulin | 18 | $30,047 | $1,669 |
| Droxidopa | None | 17 | $29,570 | $1,739 |
| Lacosamide | None | 89 | $28,745 | $323 |
| Fycompa | None | 18 | $27,656 | $1,536 |
| Briviact | None | 20 | $26,874 | $1,344 |
| Neupro | None | 17 | $23,872 | $1,404 |
| Dysport | None | 16 | $22,836 | $1,427 |
| Rasagiline Mesylate | None | 52 | $18,199 | $350 |
| Qulipta | None | 12 | $16,632 | $1,386 |
| Carbidopa-Levodopa | None | 305 | $9,943 | $33 |
| Aripiprazole | None | 44 | $9,167 | $208 |
| Carbidopa-Levodopa Er | None | 127 | $7,786 | $61 |
| Levetiracetam | None | 101 | $7,066 | $70 |
| Donepezil | None | 493 | $6,433 | $13 |
| Jardiance | None | 11 | $6,306 | $573 |
| Gabapentin | None | 330 | $5,885 | $18 |
| Entacapone | None | 13 | $4,580 | $352 |
| Memantine Hcl Er | None | 11 | $4,107 | $373 |
| Carbamazepine Er | None | 15 | $3,900 | $260 |
| Levetiracetam Er | None | 33 | $3,430 | $104 |
| Dalfampridine Er | None | 11 | $3,142 | $286 |
| Pregabalin | None | 128 | $3,041 | $24 |
| Amantadine | None | 42 | $2,880 | $69 |
| Midodrine | None | 17 | $2,806 | $165 |
| Hydrocodone-Acetaminophen | None | 88 | $2,730 | $31 |
| Baclofen | None | 36 | $2,486 | $69 |
| Mycophenolate Mofetil | None | 23 | $2,395 | $104 |
| Desvenlafaxine Succinate Er | None | 35 | $2,352 | $67 |
| Quetiapine | None | 75 | $2,282 | $30 |
| Primidone | None | 73 | $2,070 | $28 |
| Pramipexole Dihydrochloride | None | 89 | $2,024 | $23 |
| Citalopram Hbr | None | 119 | $1,920 | $16 |
| Pyridostigmine | None | 13 | $1,915 | $147 |
| Duloxetine | None | 84 | $1,883 | $22 |
| Buprenorphine | None | 13 | $1,379 | $106 |
| Morphine Sulfate Er | None | 21 | $1,331 | $63 |
| Propranolol | None | 99 | $1,329 | $13 |
| Propranolol Hcl Er | None | 27 | $1,293 | $48 |
| Clonazepam | None | 126 | $1,113 | $9 |
| Oxycodone-Acetaminophen | None | 32 | $1,072 | $34 |
| Diclofenac | None | 40 | $1,052 | $26 |
| Hydroxyzine | None | 56 | $982 | $18 |
| Escitalopram | None | 77 | $835 | $11 |
| Lamotrigine | None | 32 | $831 | $26 |
| Tramadol | None | 82 | $827 | $10 |
| Nortriptyline | None | 50 | $813 | $16 |
| Tizanidine | None | 73 | $725 | $10 |
| Glycopyrrolate | None | 13 | $685 | $53 |
| Phenobarbital | None | 18 | $660 | $37 |
| Topiramate | None | 65 | $640 | $10 |
| Mirtazapine | None | 24 | $564 | $23 |
| Ropinirole | None | 18 | $510 | $28 |
| Carbamazepine | None | 12 | $359 | $30 |
| Zolpidem | None | 25 | $345 | $14 |
| Alprazolam | None | 33 | $337 | $10 |
| Morphine Sulfate | None | 12 | $332 | $28 |
| Lorazepam | None | 68 | $319 | $5 |
| Oxycodone | None | 11 | $309 | $28 |
| Sumatriptan | None | 20 | $248 | $12 |
| Sertraline | None | 21 | $246 | $12 |
| Sodium Chloride | None | 29 | $244 | $8 |
| Temazepam | None | 14 | $234 | $17 |
| Prednisone | None | 47 | $220 | $5 |
| Celecoxib | None | 11 | $207 | $19 |
| Methylprednisolone Sodium Succ | None | 25 | $180 | $7 |
| Dicyclomine | None | 12 | $176 | $15 |
| Trazodone | None | 24 | $165 | $7 |
| Cyclobenzaprine | None | 15 | $159 | $11 |
| Meclizine | None | 18 | $150 | $8 |
| Hydrochlorothiazide | None | 11 | $125 | $11 |
| Diazepam | None | 18 | $101 | $6 |
| Zonisamide | None | 13 | $97 | $7 |
| Clopidogrel | None | 13 | $97 | $7 |
| Methocarbamol | None | 15 | $86 | $6 |
| Amitriptyline | None | 21 | $84 | $4 |
Year by year
| 2024 | 6,167 | 1,020 | 5% (278) | 16% | $3,831,453 |
| 2023 | 5,596 | 950 | 8% (430) | 19% | $4,062,721 |
| 2022 | 6,218 | 888 | 7% (440) | 21% | $6,120,922 |
| 2021 | 7,034 | 865 | 8% (544) | 21% | $5,544,443 |
| 2020 | 6,225 | 768 | 11% (676) | 21% | $3,221,429 |
| 2019 | 5,371 | 689 | 13% (716) | 24% | $2,234,695 |
| 2018 | 5,238 | 604 | 14% (728) | 25% | $2,565,151 |
| 2017 | 4,871 | 515 | 18% (853) | 24% | $2,885,531 |
| 2016 | 5,792 | 593 | 15% (890) | 22% | $2,587,823 |
| 2015 | 6,798 | 683 | 17% (1,167) | 23% | $2,640,472 |
| 2014 | 6,768 | 699 | 18% (1,230) | 24% | $2,583,273 |
| 2013 | 6,972 | 685 | 20% (1,380) | 25% | $1,563,190 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 92 drugs
| Octagam | Immune globulin | 22 | $659,052 | $29,957 |
| Gamunex-C | Immune globulin | 41 | $374,203 | $9,127 |
| Gammagard Liquid | Immune globulin | 11 | $302,391 | $27,490 |
| Gammaplex | Immune globulin | 14 | $224,542 | $16,039 |
| Ingrezza | None | 25 | $201,131 | $8,045 |
| Rytary | Parkinson's | 229 | $158,618 | $693 |
| Kesimpta | None | 13 | $107,805 | $8,293 |
| Zeposia | None | 12 | $106,822 | $8,902 |
| Xcopri | None | 59 | $104,235 | $1,767 |
| Nuplazid | Parkinson's psychosis | 17 | $84,412 | $4,965 |
| Copaxone | None | 13 | $73,947 | $5,688 |
| Botox | None | 51 | $68,055 | $1,334 |
| Rexulti | None | 26 | $46,636 | $1,794 |
| Neupro | None | 35 | $45,976 | $1,314 |
| Lacosamide | None | 71 | $42,040 | $592 |
| Fycompa | None | 26 | $40,354 | $1,552 |
| Briviact | None | 26 | $33,683 | $1,296 |
| Memantine | None | 596 | $31,011 | $52 |
| Emgality | Migraine | 34 | $29,400 | $865 |
| Aimovig | Migraine | 24 | $29,346 | $1,223 |
| Privigen | Immune globulin | 26 | $25,980 | $999 |
| Xtampza Er | None | 23 | $24,646 | $1,072 |
| Carbidopa-Levodopa | None | 299 | $21,466 | $72 |
| Rasagiline Mesylate | None | 49 | $20,937 | $427 |
| Carbidopa-Levodopa Er | None | 130 | $16,546 | $127 |
| Qulipta | None | 14 | $14,773 | $1,055 |
| Zembrace Symtouch | None | 20 | $14,620 | $731 |
| Namzaric | None | 12 | $12,029 | $1,002 |
| Donepezil | None | 481 | $10,109 | $21 |
| Ongentys | None | 12 | $8,748 | $729 |
| Pregabalin | None | 117 | $8,360 | $71 |
| Levetiracetam | None | 117 | $7,877 | $67 |
| Gabapentin | None | 370 | $7,672 | $21 |
| Levetiracetam Er | None | 11 | $4,836 | $440 |
| Entacapone | None | 13 | $4,547 | $350 |
| Hydrocodone-Acetaminophen | None | 125 | $3,941 | $32 |
| Carbidopa-Levodopa-Entacapone | None | 17 | $3,855 | $227 |
| Amantadine | None | 34 | $3,732 | $110 |
| Pyridostigmine | None | 43 | $3,353 | $78 |
| Aripiprazole | None | 34 | $3,308 | $97 |
| Carbamazepine Er | None | 11 | $3,125 | $284 |
| Midodrine | None | 14 | $2,913 | $208 |
| Pramipexole Dihydrochloride | None | 80 | $2,855 | $36 |
| Primidone | None | 51 | $2,577 | $51 |
| Propranolol | None | 102 | $2,466 | $24 |
| Quetiapine | None | 80 | $2,386 | $30 |
| Mycophenolate Mofetil | None | 29 | $2,292 | $79 |
| Lamotrigine | None | 69 | $2,284 | $33 |
| Ropinirole | None | 24 | $2,178 | $91 |
| Oxycodone-Acetaminophen | None | 52 | $2,110 | $41 |
| Duloxetine | None | 51 | $2,085 | $41 |
| Glycopyrrolate | None | 22 | $1,942 | $88 |
| Clonazepam | None | 107 | $1,879 | $18 |
| Citalopram Hbr | None | 143 | $1,799 | $13 |
| Morphine Sulfate Er | None | 33 | $1,751 | $53 |
| Baclofen | None | 27 | $1,713 | $63 |
| Phenobarbital | None | 38 | $1,602 | $42 |
| Desvenlafaxine Succinate Er | None | 25 | $1,579 | $63 |
| Tramadol | None | 92 | $1,486 | $16 |
| Celecoxib | None | 28 | $1,188 | $42 |
| Topiramate | None | 68 | $1,138 | $17 |
| Propranolol Hcl Er | None | 19 | $1,088 | $57 |
| Lorazepam | None | 57 | $1,068 | $19 |
| Carbamazepine | None | 11 | $995 | $90 |
| Diclofenac | None | 30 | $873 | $29 |
| Escitalopram | None | 42 | $839 | $20 |
| Tizanidine | None | 48 | $833 | $17 |
| Butalbital-Acetaminophen-Caffe | None | 20 | $772 | $39 |
| Hydroxyzine | None | 24 | $659 | $27 |
| Bupropion Xl | None | 14 | $589 | $42 |
| Clopidogrel | None | 24 | $512 | $21 |
| Buspirone | None | 15 | $496 | $33 |
| Sumatriptan | None | 27 | $484 | $18 |
| Temazepam | None | 26 | $480 | $18 |
| Risperidone | None | 13 | $418 | $32 |
| Morphine Sulfate | None | 13 | $384 | $30 |
| Zolpidem | None | 23 | $330 | $14 |
| Oxycodone | None | 16 | $311 | $19 |
| Fludrocortisone Acetate | None | 11 | $297 | $27 |
| Naratriptan | None | 11 | $286 | $26 |
| Ondansetron Odt | None | 12 | $277 | $23 |
| Sodium Chloride | None | 20 | $265 | $13 |
| Methadone | None | 13 | $260 | $20 |
| Trazodone | None | 44 | $250 | $6 |
| Diazepam | None | 35 | $231 | $7 |
| Alprazolam | None | 16 | $208 | $13 |
| Prednisone | None | 16 | $182 | $11 |
| Nortriptyline | None | 12 | $156 | $13 |
| Sertraline | None | 21 | $145 | $7 |
| Acetaminophen-Codeine | None | 14 | $129 | $9 |
| Rizatriptan | None | 16 | $124 | $8 |
| Amitriptyline | None | 14 | $113 | $8 |
2022: 110 drugs
| Gammagard Liquid | Immune globulin | 60 | $667,331 | $11,122 |
| Cuvitru | Immune globulin | 13 | $438,004 | $33,693 |
| Austedo | None | 33 | $365,413 | $11,073 |
| Octagam | Immune globulin | 12 | $309,831 | $25,819 |
| Northera | None | 18 | $254,776 | $14,154 |
| Ingrezza | None | 32 | $234,264 | $7,321 |
| Gammaplex | Immune globulin | 13 | $208,940 | $16,072 |
| Gamunex-C | Immune globulin | 25 | $173,124 | $6,925 |
| Rytary | Parkinson's | 221 | $158,721 | $718 |
| Copaxone | None | 27 | $158,540 | $5,872 |
| Kesimpta | None | 17 | $146,383 | $8,611 |
| Tecfidera | None | 19 | $138,976 | $7,315 |
| Xcopri | None | 75 | $118,238 | $1,577 |
| Bafiertam | None | 17 | $110,391 | $6,494 |
| Avonex | None | 13 | $103,156 | $7,935 |
| Zeposia | None | 12 | $99,112 | $8,259 |
| Nuplazid | Parkinson's psychosis | 13 | $61,022 | $4,694 |
| Nourianz | None | 28 | $55,522 | $1,983 |
| Briviact | None | 54 | $54,020 | $1,000 |
| Vimpat | None | 42 | $48,987 | $1,166 |
| Glatiramer Acetate | None | 11 | $47,342 | $4,304 |
| Neupro | None | 30 | $46,971 | $1,566 |
| Botox | None | 35 | $42,379 | $1,211 |
| Rasagiline Mesylate | None | 64 | $37,840 | $591 |
| Fycompa | None | 26 | $37,662 | $1,449 |
| Nuedexta | None | 16 | $36,942 | $2,309 |
| Xtampza Er | None | 30 | $30,794 | $1,026 |
| Carbidopa-Levodopa | None | 370 | $27,052 | $73 |
| Privigen | Immune globulin | 26 | $23,848 | $917 |
| Zembrace Symtouch | None | 32 | $21,766 | $680 |
| Lacosamide | None | 42 | $21,613 | $515 |
| Namzaric | None | 21 | $20,457 | $974 |
| Emgality | Migraine | 28 | $20,436 | $730 |
| Memantine | None | 391 | $19,948 | $51 |
| Nurtec Odt | None | 15 | $19,571 | $1,305 |
| Aimovig | Migraine | 19 | $16,648 | $876 |
| Carbidopa-Levodopa Er | None | 153 | $15,736 | $103 |
| Entacapone | None | 43 | $15,387 | $358 |
| Levetiracetam | None | 162 | $14,414 | $89 |
| Carbamazepine Er | None | 25 | $13,055 | $522 |
| Horizant | None | 13 | $12,926 | $994 |
| Belbuca | None | 13 | $10,834 | $833 |
| Gabapentin | None | 407 | $9,872 | $24 |
| Pregabalin | None | 99 | $9,872 | $100 |
| Quetiapine | None | 138 | $9,551 | $69 |
| Oxtellar Xr | None | 12 | $8,584 | $715 |
| Ongentys | None | 12 | $8,315 | $693 |
| Duloxetine | None | 77 | $7,220 | $94 |
| Donepezil | None | 350 | $6,089 | $17 |
| Hydrocodone Bitartrate Er | None | 11 | $5,782 | $526 |
| Dalfampridine Er | None | 21 | $5,399 | $257 |
| Memantine Hcl Er | None | 22 | $5,252 | $239 |
| Carbidopa-Levodopa-Entacapone | None | 27 | $5,183 | $192 |
| Brilinta | None | 11 | $4,989 | $454 |
| Midodrine | None | 36 | $4,431 | $123 |
| Amantadine | None | 36 | $4,426 | $123 |
| Pyridostigmine | None | 38 | $3,998 | $105 |
| Hydrocodone-Acetaminophen | None | 114 | $3,784 | $33 |
| Carbamazepine | None | 25 | $3,606 | $144 |
| Aripiprazole | None | 19 | $2,897 | $152 |
| Morphine Sulfate Er | None | 41 | $2,866 | $70 |
| Clonazepam | None | 148 | $2,784 | $19 |
| Lidocaine | None | 13 | $2,551 | $196 |
| Propranolol Hcl Er | None | 30 | $2,551 | $85 |
| Lamotrigine | None | 88 | $2,469 | $28 |
| Phenobarbital | None | 40 | $2,413 | $60 |
| Baclofen | None | 45 | $2,222 | $49 |
| Oxycodone-Acetaminophen | None | 49 | $2,198 | $45 |
| Pramipexole Dihydrochloride | None | 95 | $2,036 | $21 |
| Ropinirole | None | 48 | $2,030 | $42 |
| Temazepam | None | 43 | $2,002 | $47 |
| Propranolol | None | 69 | $1,869 | $27 |
| Mycophenolate Mofetil | None | 24 | $1,739 | $72 |
| Risperidone Odt | None | 13 | $1,734 | $133 |
| Topiramate | None | 71 | $1,685 | $24 |
| Celecoxib | None | 21 | $1,401 | $67 |
| Tizanidine | None | 77 | $1,333 | $17 |
| Citalopram Hbr | None | 216 | $1,320 | $6 |
| Modafinil | None | 13 | $1,300 | $100 |
| Primidone | None | 49 | $1,196 | $24 |
| Bupropion Xl | None | 22 | $1,179 | $54 |
| Buspirone | None | 46 | $878 | $19 |
| Methylphenidate | None | 12 | $862 | $72 |
| Diclofenac | None | 39 | $848 | $22 |
| Tramadol | None | 92 | $787 | $9 |
| Zolmitriptan | None | 11 | $753 | $68 |
| Sumatriptan | None | 43 | $748 | $17 |
| Fludrocortisone Acetate | None | 27 | $726 | $27 |
| Morphine Sulfate | None | 21 | $658 | $31 |
| Divalproex Sodium Er | None | 22 | $556 | $25 |
| Escitalopram | None | 55 | $547 | $10 |
| Clopidogrel | None | 34 | $461 | $14 |
| Cyclobenzaprine | None | 30 | $461 | $15 |
| Nortriptyline | None | 16 | $434 | $27 |
| Lorazepam | None | 57 | $399 | $7 |
| Mirtazapine | None | 14 | $345 | $25 |
| Methadone | None | 17 | $324 | $19 |
| Alprazolam | None | 15 | $296 | $20 |
| Omeprazole | None | 18 | $288 | $16 |
| Trazodone | None | 29 | $258 | $9 |
| Diazepam | None | 44 | $255 | $6 |
| Zolpidem | None | 23 | $233 | $10 |
| Meclizine | None | 18 | $232 | $13 |
| Sodium Chloride | None | 15 | $177 | $12 |
| Acetaminophen-Codeine | None | 11 | $165 | $15 |
| Amitriptyline | None | 11 | $136 | $12 |
| Hydroxyzine | None | 11 | $132 | $12 |
| Prednisone | None | 15 | $119 | $8 |
| Fluoxetine | None | 18 | $81 | $4 |
| Atorvastatin | None | 11 | $78 | $7 |
2021: 114 drugs
| Gammaplex | Immune globulin | 28 | $587,251 | $20,973 |
| Gammagard Liquid | Immune globulin | 30 | $324,922 | $10,831 |
| Northera | None | 25 | $289,554 | $11,582 |
| Ingrezza | None | 32 | $230,393 | $7,200 |
| Nuplazid | Parkinson's psychosis | 55 | $220,162 | $4,003 |
| Tecfidera | None | 29 | $206,086 | $7,106 |
| Gamunex-C | Immune globulin | 34 | $183,880 | $5,408 |
| Austedo | None | 15 | $169,902 | $11,327 |
| Copaxone | None | 27 | $160,340 | $5,939 |
| Rytary | Parkinson's | 211 | $143,008 | $678 |
| Vimpat | None | 118 | $135,330 | $1,147 |
| Avonex | None | 13 | $98,924 | $7,610 |
| Xcopri | None | 60 | $82,576 | $1,376 |
| Nourianz | None | 39 | $79,456 | $2,037 |
| Neupro | None | 70 | $61,782 | $883 |
| Droxidopa | None | 13 | $60,673 | $4,667 |
| Trokendi Xr | None | 32 | $57,104 | $1,785 |
| Glatiramer Acetate | None | 12 | $56,630 | $4,719 |
| Briviact | None | 48 | $40,767 | $849 |
| Rasagiline Mesylate | None | 78 | $39,078 | $501 |
| Xtampza Er | None | 39 | $35,553 | $912 |
| Nuedexta | None | 22 | $33,829 | $1,538 |
| Nurtec Odt | None | 25 | $31,839 | $1,274 |
| Botox | None | 22 | $29,745 | $1,352 |
| Carbidopa-Levodopa | None | 410 | $26,131 | $64 |
| Fycompa | None | 21 | $25,579 | $1,218 |
| Emgality | Migraine | 35 | $24,080 | $688 |
| Privigen | Immune globulin | 23 | $23,990 | $1,043 |
| Aimovig | Migraine | 25 | $16,522 | $661 |
| Rexulti | None | 12 | $15,713 | $1,309 |
| Namzaric | None | 21 | $13,528 | $644 |
| Trintellix | None | 19 | $13,517 | $711 |
| Memantine | None | 323 | $13,170 | $41 |
| Carbidopa-Levodopa Er | None | 150 | $12,350 | $82 |
| Levetiracetam | None | 176 | $11,965 | $68 |
| Gabapentin | None | 498 | $11,208 | $23 |
| Horizant | None | 11 | $10,950 | $995 |
| Oxtellar Xr | None | 15 | $9,635 | $642 |
| Myrbetriq | None | 22 | $9,420 | $428 |
| Entacapone | None | 40 | $9,269 | $232 |
| Carbamazepine Er | None | 21 | $8,959 | $427 |
| Memantine Hcl Er | None | 18 | $8,793 | $488 |
| Carbidopa-Levodopa-Entacapone | None | 34 | $8,551 | $251 |
| Pregabalin | None | 87 | $7,590 | $87 |
| Quetiapine | None | 160 | $6,041 | $38 |
| Donepezil | None | 370 | $5,818 | $16 |
| Dexilant | None | 15 | $4,679 | $312 |
| Baclofen | None | 41 | $4,640 | $113 |
| Duloxetine | None | 80 | $3,909 | $49 |
| Pramipexole Dihydrochloride | None | 133 | $3,743 | $28 |
| Phenobarbital | None | 69 | $3,467 | $50 |
| Hydrocodone-Acetaminophen | None | 140 | $3,452 | $25 |
| Midodrine | None | 28 | $2,951 | $105 |
| Morphine Sulfate Er | None | 35 | $2,931 | $84 |
| Carbamazepine | None | 31 | $2,929 | $94 |
| Lidocaine | None | 20 | $2,703 | $135 |
| Lamotrigine | None | 132 | $2,600 | $20 |
| Azathioprine | None | 12 | $2,558 | $213 |
| Pyridostigmine | None | 20 | $2,479 | $124 |
| Clonazepam | None | 159 | $2,453 | $15 |
| Desvenlafaxine Succinate Er | None | 13 | $2,400 | $185 |
| Butalbital-Acetaminophen-Caffe | None | 21 | $2,204 | $105 |
| Propranolol | None | 76 | $2,064 | $27 |
| Oxycodone-Acetaminophen | None | 64 | $1,930 | $30 |
| Amantadine | None | 22 | $1,902 | $86 |
| Temazepam | None | 74 | $1,839 | $25 |
| Diclofenac | None | 60 | $1,680 | $28 |
| Propranolol Hcl Er | None | 33 | $1,540 | $47 |
| Tizanidine | None | 97 | $1,478 | $15 |
| Phenytoin Sodium Extended | None | 22 | $1,409 | $64 |
| Citalopram Hbr | None | 273 | $1,318 | $5 |
| Divalproex Sodium Er | None | 25 | $1,226 | $49 |
| Methylphenidate | None | 19 | $1,174 | $62 |
| Risperidone Odt | None | 14 | $1,170 | $84 |
| Dalfampridine Er | None | 12 | $1,154 | $96 |
| Galantamine Hbr | None | 14 | $1,091 | $78 |
| Primidone | None | 39 | $1,061 | $27 |
| Venlafaxine Hcl Er | None | 25 | $1,014 | $41 |
| Clopidogrel | None | 76 | $944 | $12 |
| Topiramate | None | 65 | $934 | $14 |
| Tramadol | None | 110 | $916 | $8 |
| Glycopyrrolate | None | 22 | $897 | $41 |
| Zonisamide | None | 26 | $872 | $34 |
| Ropinirole | None | 42 | $857 | $20 |
| Mirtazapine | None | 27 | $843 | $31 |
| Nortriptyline | None | 37 | $771 | $21 |
| Cyclobenzaprine | None | 54 | $752 | $14 |
| Escitalopram | None | 56 | $721 | $13 |
| Bupropion Xl | None | 18 | $703 | $39 |
| Buspirone | None | 48 | $700 | $15 |
| Fludrocortisone Acetate | None | 29 | $681 | $23 |
| Aripiprazole | None | 12 | $608 | $51 |
| Sumatriptan | None | 27 | $540 | $20 |
| Lorazepam | None | 64 | $535 | $8 |
| Hydromorphone | None | 18 | $517 | $29 |
| Zolpidem | None | 56 | $464 | $8 |
| Methadone | None | 25 | $460 | $18 |
| Morphine Sulfate | None | 13 | $392 | $30 |
| Diazepam | None | 62 | $375 | $6 |
| Alprazolam | None | 25 | $373 | $15 |
| Fluoxetine | None | 17 | $353 | $21 |
| Acetaminophen-Codeine | None | 37 | $342 | $9 |
| Hydroxyzine Pamoate | None | 13 | $342 | $26 |
| Hydroxyzine | None | 25 | $332 | $13 |
| Ondansetron | None | 12 | $329 | $27 |
| Sertraline | None | 33 | $258 | $8 |
| Meclizine | None | 20 | $248 | $12 |
| Trazodone | None | 17 | $165 | $10 |
| Prednisone | None | 35 | $155 | $4 |
| Risperidone | None | 15 | $144 | $10 |
| Ibuprofen | None | 18 | $122 | $7 |
| Sodium Chloride | None | 12 | $110 | $9 |
| Amitriptyline | None | 11 | $49 | $4 |
| Metoprolol | None | 11 | $37 | $3 |
2020: 112 drugs
| Gammaplex | Immune globulin | 36 | $432,358 | $12,010 |
| Gamunex-C | Immune globulin | 52 | $234,300 | $4,506 |
| Nuplazid | Parkinson's psychosis | 47 | $168,935 | $3,594 |
| Avonex | None | 17 | $162,937 | $9,585 |
| Northera | None | 17 | $148,189 | $8,717 |
| Vimpat | None | 130 | $126,921 | $976 |
| Copaxone | None | 21 | $123,433 | $5,878 |
| Austedo | None | 13 | $123,029 | $9,464 |
| Tecfidera | None | 22 | $122,404 | $5,564 |
| Rytary | Parkinson's | 199 | $105,691 | $531 |
| Aubagio | None | 13 | $104,868 | $8,067 |
| Ingrezza | None | 15 | $96,776 | $6,452 |
| Privigen | Immune globulin | 15 | $67,008 | $4,467 |
| Glatiramer Acetate | None | 14 | $66,068 | $4,719 |
| Trokendi Xr | None | 21 | $44,304 | $2,110 |
| Neupro | None | 52 | $40,428 | $777 |
| Nucynta | None | 25 | $37,989 | $1,520 |
| Briviact | None | 42 | $36,915 | $879 |
| Nourianz | None | 14 | $32,593 | $2,328 |
| Xtampza Er | None | 48 | $31,806 | $663 |
| Nurtec Odt | None | 36 | $30,513 | $848 |
| Emgality | Migraine | 37 | $23,721 | $641 |
| Rasagiline Mesylate | None | 48 | $22,619 | $471 |
| Oxycontin | None | 29 | $21,022 | $725 |
| Namzaric | None | 25 | $20,267 | $811 |
| Xcopri | None | 19 | $19,156 | $1,008 |
| Aptiom | None | 15 | $17,738 | $1,183 |
| Carbidopa-Levodopa | None | 300 | $17,234 | $57 |
| Fycompa | None | 16 | $15,842 | $990 |
| Carbidopa-Levodopa Er | None | 151 | $14,765 | $98 |
| Horizant | None | 12 | $14,381 | $1,198 |
| Nuedexta | None | 11 | $12,883 | $1,171 |
| Memantine | None | 314 | $12,817 | $41 |
| Carbamazepine Er | None | 36 | $11,801 | $328 |
| Pregabalin | None | 112 | $11,087 | $99 |
| Butrans | None | 13 | $9,748 | $750 |
| Carbidopa-Levodopa-Entacapone | None | 30 | $9,545 | $318 |
| Linzess | None | 14 | $8,332 | $595 |
| Memantine Hcl Er | None | 14 | $7,701 | $550 |
| Gabapentin | None | 381 | $6,928 | $18 |
| Entacapone | None | 17 | $6,867 | $404 |
| Belbuca | None | 17 | $6,791 | $399 |
| Levetiracetam | None | 129 | $5,917 | $46 |
| Rivastigmine | None | 15 | $5,845 | $390 |
| Duloxetine | None | 112 | $5,806 | $52 |
| Viibryd | None | 14 | $5,729 | $409 |
| Amantadine | None | 64 | $4,825 | $75 |
| Donepezil | None | 301 | $4,462 | $15 |
| Hydrocodone-Acetaminophen | None | 186 | $3,773 | $20 |
| Lidocaine | None | 24 | $3,560 | $148 |
| Phenobarbital | None | 43 | $3,559 | $83 |
| Carbamazepine | None | 39 | $3,259 | $84 |
| Tizanidine | None | 122 | $3,197 | $26 |
| Pramipexole Dihydrochloride | None | 102 | $3,167 | $31 |
| Pyridostigmine | None | 30 | $2,968 | $99 |
| Dilantin | None | 15 | $2,955 | $197 |
| Morphine Sulfate Er | None | 46 | $2,725 | $59 |
| Diclofenac | None | 59 | $2,353 | $40 |
| Butalbital-Acetaminophen-Caffe | None | 31 | $2,115 | $68 |
| Baclofen | None | 49 | $2,097 | $43 |
| Quetiapine | None | 83 | $2,045 | $25 |
| Propranolol | None | 59 | $1,767 | $30 |
| Clonazepam | None | 113 | $1,766 | $16 |
| Ropinirole | None | 57 | $1,735 | $30 |
| Oxycodone-Acetaminophen | None | 62 | $1,722 | $28 |
| Desvenlafaxine Succinate Er | None | 13 | $1,676 | $129 |
| Midodrine | None | 14 | $1,542 | $110 |
| Topiramate | None | 76 | $1,516 | $20 |
| Divalproex Sodium Er | None | 37 | $1,468 | $40 |
| Azathioprine | None | 17 | $1,407 | $83 |
| Clopidogrel | None | 85 | $1,372 | $16 |
| Primidone | None | 41 | $1,313 | $32 |
| Lamotrigine | None | 53 | $1,280 | $24 |
| Galantamine Hbr | None | 19 | $1,168 | $61 |
| Hydromorphone | None | 23 | $946 | $41 |
| Hydroxyzine | None | 39 | $919 | $24 |
| Tramadol | None | 114 | $918 | $8 |
| Phenytoin | None | 11 | $748 | $68 |
| Alprazolam | None | 60 | $737 | $12 |
| Temazepam | None | 53 | $732 | $14 |
| Methylphenidate | None | 21 | $717 | $34 |
| Propranolol Hcl Er | None | 12 | $698 | $58 |
| Citalopram Hbr | None | 138 | $693 | $5 |
| Escitalopram | None | 64 | $655 | $10 |
| Bupropion Xl | None | 11 | $633 | $58 |
| Fludrocortisone Acetate | None | 25 | $573 | $23 |
| Divalproex | None | 18 | $523 | $29 |
| Lorazepam | None | 62 | $517 | $8 |
| Sumatriptan | None | 39 | $513 | $13 |
| Oxycodone | None | 28 | $464 | $17 |
| Cyclobenzaprine | None | 36 | $448 | $12 |
| Diazepam | None | 66 | $428 | $6 |
| Zolpidem | None | 48 | $416 | $9 |
| Methadone | None | 21 | $347 | $17 |
| Morphine Sulfate | None | 14 | $342 | $24 |
| Acetaminophen-Codeine | None | 21 | $338 | $16 |
| Sodium Chloride | None | 29 | $326 | $11 |
| Sertraline | None | 42 | $301 | $7 |
| Nortriptyline | None | 21 | $282 | $13 |
| Buspirone | None | 16 | $275 | $17 |
| Trihexyphenidyl | None | 12 | $269 | $22 |
| Hydroxyzine Pamoate | None | 21 | $266 | $13 |
| Zonisamide | None | 14 | $242 | $17 |
| Fluoxetine | None | 14 | $203 | $14 |
| Amitriptyline | None | 14 | $189 | $14 |
| Meclizine | None | 12 | $168 | $14 |
| Risperidone | None | 22 | $167 | $8 |
| Ibuprofen | None | 25 | $161 | $6 |
| Omeprazole | None | 11 | $86 | $8 |
| Trazodone | None | 13 | $84 | $6 |
| Alendronate | None | 11 | $58 | $5 |
| Prednisone | None | 12 | $56 | $5 |
2019: 108 drugs
| Copaxone | None | 37 | $211,860 | $5,726 |
| Avonex | None | 20 | $205,118 | $10,256 |
| Nuplazid | Parkinson's psychosis | 47 | $148,258 | $3,154 |
| Tecfidera | None | 12 | $111,582 | $9,298 |
| Vimpat | None | 93 | $105,132 | $1,130 |
| Austedo | None | 11 | $95,763 | $8,706 |
| Rytary | Parkinson's | 219 | $93,092 | $425 |
| Gamunex-C | Immune globulin | 14 | $78,856 | $5,633 |
| Lyrica | None | 80 | $67,638 | $845 |
| Nuedexta | None | 50 | $59,978 | $1,200 |
| Northera | None | 11 | $45,501 | $4,136 |
| Nucynta | None | 31 | $38,187 | $1,232 |
| Namzaric | None | 44 | $36,414 | $828 |
| Privigen | Immune globulin | 15 | $34,486 | $2,299 |
| Neupro | None | 42 | $31,810 | $757 |
| Aptiom | None | 29 | $30,440 | $1,050 |
| Briviact | None | 29 | $28,954 | $998 |
| Fycompa | None | 36 | $28,573 | $794 |
| Xtampza Er | None | 55 | $28,351 | $515 |
| Trokendi Xr | None | 16 | $21,990 | $1,374 |
| Rasagiline Mesylate | None | 32 | $20,891 | $653 |
| Butrans | None | 20 | $13,350 | $667 |
| Memantine | None | 228 | $11,381 | $50 |
| Carbidopa-Levodopa Er | None | 131 | $11,129 | $85 |
| Emgality | Migraine | 18 | $10,686 | $594 |
| Embeda | None | 12 | $10,157 | $846 |
| Oxymorphone Hcl Er | None | 21 | $9,855 | $469 |
| Rivastigmine | None | 29 | $9,612 | $331 |
| Carbidopa-Levodopa | None | 207 | $9,121 | $44 |
| Carbidopa-Levodopa-Entacapone | None | 25 | $8,274 | $331 |
| Duloxetine | None | 101 | $7,640 | $76 |
| Carbamazepine Er | None | 28 | $7,454 | $266 |
| Gabapentin | None | 316 | $7,281 | $23 |
| Linzess | None | 17 | $7,279 | $428 |
| Oxycontin | None | 13 | $6,700 | $515 |
| Amantadine | None | 26 | $4,807 | $185 |
| Hydrocodone-Acetaminophen | None | 189 | $4,520 | $24 |
| Levetiracetam | None | 132 | $4,398 | $33 |
| Desvenlafaxine Succinate Er | None | 23 | $4,272 | $186 |
| Divalproex Sodium Er | None | 59 | $4,152 | $70 |
| Pregabalin | None | 35 | $3,981 | $114 |
| Belbuca | None | 12 | $3,929 | $327 |
| Donepezil | None | 199 | $3,772 | $19 |
| Lidocaine | None | 19 | $3,700 | $195 |
| Carbamazepine | None | 40 | $3,649 | $91 |
| Phenobarbital | None | 45 | $3,014 | $67 |
| Fentanyl | None | 20 | $2,634 | $132 |
| Ropinirole | None | 49 | $2,451 | $50 |
| Pyridostigmine | None | 26 | $2,326 | $89 |
| Morphine Sulfate Er | None | 24 | $2,116 | $88 |
| Propranolol | None | 70 | $2,096 | $30 |
| Tizanidine | None | 90 | $2,067 | $23 |
| Amitiza | None | 12 | $2,037 | $170 |
| Pramipexole Dihydrochloride | None | 77 | $1,946 | $25 |
| Voltaren | None | 23 | $1,916 | $83 |
| Modafinil | None | 12 | $1,756 | $146 |
| Diclofenac | None | 23 | $1,748 | $76 |
| Quetiapine | None | 82 | $1,586 | $19 |
| Azathioprine | None | 28 | $1,520 | $54 |
| Escitalopram | None | 59 | $1,459 | $25 |
| Baclofen | None | 35 | $1,418 | $41 |
| Primidone | None | 53 | $1,307 | $25 |
| Tolterodine Tartrate Er | None | 12 | $1,238 | $103 |
| Clopidogrel | None | 60 | $1,141 | $19 |
| Oxycodone-Acetaminophen | None | 37 | $1,127 | $30 |
| Butalbital-Acetaminophen-Caffe | None | 15 | $1,110 | $74 |
| Midodrine | None | 12 | $1,095 | $91 |
| Tramadol | None | 117 | $1,072 | $9 |
| Lamotrigine | None | 48 | $1,071 | $22 |
| Phenytoin | None | 19 | $1,045 | $55 |
| Bupropion Xl | None | 13 | $976 | $75 |
| Propranolol Hcl Er | None | 11 | $968 | $88 |
| Topiramate | None | 43 | $928 | $22 |
| Alprazolam | None | 67 | $884 | $13 |
| Methylphenidate | None | 15 | $833 | $56 |
| Clonazepam | None | 102 | $795 | $8 |
| Divalproex | None | 28 | $745 | $27 |
| Hydromorphone | None | 22 | $700 | $32 |
| Oxycodone | None | 29 | $643 | $22 |
| Citalopram Hbr | None | 90 | $589 | $7 |
| Morphine Sulfate | None | 26 | $587 | $23 |
| Galantamine Hbr | None | 11 | $533 | $48 |
| Amitriptyline | None | 29 | $497 | $17 |
| Zolpidem | None | 55 | $489 | $9 |
| Phenytoin Sodium Extended | None | 11 | $454 | $41 |
| Temazepam | None | 67 | $426 | $6 |
| Methadone | None | 23 | $371 | $16 |
| Acetaminophen-Codeine | None | 31 | $331 | $11 |
| Sertraline | None | 29 | $328 | $11 |
| Nortriptyline | None | 23 | $315 | $14 |
| Diazepam | None | 52 | $309 | $6 |
| Lorazepam | None | 50 | $303 | $6 |
| Sumatriptan | None | 20 | $292 | $15 |
| Eszopiclone | None | 11 | $278 | $25 |
| Mirtazapine | None | 16 | $270 | $17 |
| Zonisamide | None | 16 | $247 | $15 |
| Cyclobenzaprine | None | 29 | $225 | $8 |
| Risperidone | None | 18 | $201 | $11 |
| Buspirone | None | 16 | $192 | $12 |
| Prednisone | None | 31 | $156 | $5 |
| Trazodone | None | 12 | $148 | $12 |
| Ibuprofen | None | 14 | $147 | $10 |
| Meloxicam | None | 15 | $137 | $9 |
| Atorvastatin | None | 16 | $128 | $8 |
| Trihexyphenidyl | None | 13 | $127 | $10 |
| Omeprazole | None | 16 | $126 | $8 |
| Lisinopril | None | 12 | $50 | $4 |
| Clonidine | None | 11 | $41 | $4 |
2018: 110 drugs
| Gamunex-C | Immune globulin | 27 | $191,411 | $7,089 |
| Copaxone | None | 28 | $169,400 | $6,050 |
| Tecfidera | None | 15 | $142,309 | $9,487 |
| Aubagio | None | 21 | $138,203 | $6,581 |
| Vimpat | None | 112 | $113,013 | $1,009 |
| Ingrezza | None | 17 | $107,723 | $6,337 |
| Avonex | None | 14 | $94,106 | $6,722 |
| Nuplazid | Parkinson's psychosis | 33 | $94,029 | $2,849 |
| Lyrica | None | 79 | $68,261 | $864 |
| Rytary | Parkinson's | 148 | $50,021 | $338 |
| Northera | None | 15 | $49,656 | $3,310 |
| Aptiom | None | 34 | $47,129 | $1,386 |
| Keppra | None | 13 | $46,531 | $3,579 |
| Butrans | None | 81 | $46,188 | $570 |
| Octagam | Immune globulin | 13 | $45,456 | $3,497 |
| Namzaric | None | 74 | $42,778 | $578 |
| Ampyra | None | 15 | $39,499 | $2,633 |
| Privigen | Immune globulin | 16 | $38,521 | $2,408 |
| Rasagiline Mesylate | None | 36 | $35,597 | $989 |
| Neupro | None | 36 | $31,387 | $872 |
| Gammagard Liquid | Immune globulin | 11 | $29,711 | $2,701 |
| Nuedexta | None | 26 | $28,524 | $1,097 |
| Fycompa | None | 38 | $28,181 | $742 |
| Briviact | None | 24 | $26,386 | $1,099 |
| Nucynta | None | 18 | $25,221 | $1,401 |
| Trokendi Xr | None | 11 | $14,849 | $1,350 |
| Carbidopa-Levodopa Er | None | 141 | $13,403 | $95 |
| Onfi | None | 13 | $12,485 | $960 |
| Xtampza Er | None | 21 | $12,375 | $589 |
| Oxymorphone Hcl Er | None | 24 | $11,771 | $490 |
| Embeda | None | 13 | $10,811 | $832 |
| Rivastigmine | None | 21 | $9,839 | $469 |
| Buprenorphine | None | 24 | $9,688 | $404 |
| Carbidopa-Levodopa | None | 228 | $9,530 | $42 |
| Zohydro Er | None | 15 | $9,325 | $622 |
| Entacapone | None | 16 | $8,224 | $514 |
| Memantine | None | 107 | $7,986 | $75 |
| Duloxetine | None | 89 | $6,082 | $68 |
| Gabapentin | None | 328 | $6,077 | $19 |
| Hydrocodone-Acetaminophen | None | 234 | $6,000 | $26 |
| Divalproex Sodium Er | None | 48 | $5,899 | $123 |
| Amantadine | None | 29 | $5,682 | $196 |
| Levetiracetam | None | 157 | $4,033 | $26 |
| Voltaren | None | 21 | $3,557 | $169 |
| Fentanyl | None | 27 | $3,463 | $128 |
| Pyridostigmine | None | 20 | $3,447 | $172 |
| Carbamazepine | None | 37 | $3,415 | $92 |
| Morphine Sulfate Er | None | 38 | $2,969 | $78 |
| Donepezil | None | 174 | $2,726 | $16 |
| Phenobarbital | None | 58 | $2,557 | $44 |
| Armodafinil | None | 12 | $2,491 | $208 |
| Desvenlafaxine Succinate Er | None | 12 | $2,271 | $189 |
| Tolterodine Tartrate Er | None | 18 | $2,198 | $122 |
| Ropinirole | None | 37 | $1,931 | $52 |
| Pramipexole Dihydrochloride | None | 79 | $1,722 | $22 |
| Baclofen | None | 50 | $1,621 | $32 |
| Methylphenidate | None | 27 | $1,355 | $50 |
| Phenytoin Sodium Extended | None | 18 | $1,339 | $74 |
| Ethosuximide | None | 11 | $1,337 | $122 |
| Escitalopram | None | 68 | $1,291 | $19 |
| Midodrine | None | 18 | $1,283 | $71 |
| Oxcarbazepine | None | 20 | $1,254 | $63 |
| Aripiprazole | None | 20 | $1,206 | $60 |
| Clopidogrel | None | 71 | $1,195 | $17 |
| Topiramate | None | 74 | $1,142 | $15 |
| Propranolol | None | 52 | $1,141 | $22 |
| Azathioprine | None | 19 | $1,105 | $58 |
| Divalproex | None | 36 | $1,098 | $30 |
| Oxycodone | None | 32 | $1,024 | $32 |
| Quetiapine | None | 86 | $988 | $11 |
| Celecoxib | None | 11 | $970 | $88 |
| Lamotrigine | None | 67 | $924 | $14 |
| Primidone | None | 37 | $872 | $24 |
| Tramadol | None | 78 | $866 | $11 |
| Levetiracetam Er | None | 14 | $864 | $62 |
| Tizanidine | None | 57 | $847 | $15 |
| Pyridostigmine Bromide Er | None | 13 | $810 | $62 |
| Oxycodone-Acetaminophen | None | 18 | $759 | $42 |
| Mirtazapine | None | 33 | $751 | $23 |
| Diclofenac | None | 12 | $670 | $56 |
| Amitriptyline | None | 46 | $663 | $14 |
| Sumatriptan | None | 15 | $570 | $38 |
| Cyclobenzaprine | None | 31 | $567 | $18 |
| Clonazepam | None | 92 | $513 | $6 |
| Temazepam | None | 42 | $471 | $11 |
| Nortriptyline | None | 42 | $468 | $11 |
| Fludrocortisone Acetate | None | 18 | $456 | $25 |
| Zolpidem | None | 43 | $446 | $10 |
| Citalopram Hbr | None | 69 | $435 | $6 |
| Butalbital-Acetaminophen-Caffe | None | 14 | $429 | $31 |
| Lorazepam | None | 71 | $394 | $6 |
| Morphine Sulfate | None | 20 | $388 | $19 |
| Methadone | None | 18 | $375 | $21 |
| Hydromorphone | None | 19 | $336 | $18 |
| Alprazolam | None | 44 | $310 | $7 |
| Bupropion Hcl Sr | None | 16 | $275 | $17 |
| Atorvastatin | None | 17 | $263 | $15 |
| Sertraline | None | 22 | $259 | $12 |
| Acetaminophen-Codeine | None | 24 | $242 | $10 |
| Diazepam | None | 33 | $234 | $7 |
| Zonisamide | None | 12 | $226 | $19 |
| Ranitidine | None | 20 | $185 | $9 |
| Prednisone | None | 18 | $178 | $10 |
| Trihexyphenidyl | None | 12 | $114 | $9 |
| Trazodone | None | 19 | $111 | $6 |
| Omeprazole | None | 15 | $93 | $6 |
| Buspirone | None | 13 | $81 | $6 |
| Dextrose in Water | None | 11 | $76 | $7 |
| Famotidine | None | 11 | $75 | $7 |
| Risperidone | None | 12 | $44 | $4 |
2017: 109 drugs
| H.P. Acthar | None | 21 | $1,077,784 | $51,323 |
| Gamunex-C | Immune globulin | 25 | $174,421 | $6,977 |
| Tetrabenazine | None | 12 | $117,532 | $9,794 |
| Privigen | Immune globulin | 18 | $116,298 | $6,461 |
| Vimpat | None | 135 | $112,655 | $834 |
| Octagam | Immune globulin | 17 | $89,718 | $5,278 |
| Aubagio | None | 11 | $79,061 | $7,187 |
| Lyrica | None | 80 | $53,813 | $673 |
| Butrans | None | 88 | $44,126 | $501 |
| Keppra | None | 12 | $42,024 | $3,502 |
| Aptiom | None | 30 | $38,539 | $1,285 |
| Rytary | Parkinson's | 73 | $29,827 | $409 |
| Oxycontin | None | 32 | $29,792 | $931 |
| Fycompa | None | 39 | $24,778 | $635 |
| Neupro | None | 28 | $21,143 | $755 |
| Namzaric | None | 46 | $20,250 | $440 |
| Onfi | None | 16 | $18,060 | $1,129 |
| Nucynta | None | 19 | $17,813 | $938 |
| Nuedexta | None | 20 | $16,844 | $842 |
| Briviact | None | 16 | $16,041 | $1,003 |
| Rasagiline Mesylate | None | 18 | $16,013 | $890 |
| Oxymorphone Hcl Er | None | 26 | $12,970 | $499 |
| Hysingla Er | None | 17 | $11,708 | $689 |
| Azilect | None | 14 | $11,226 | $802 |
| Carbidopa-Levodopa-Entacapone | None | 20 | $10,961 | $548 |
| Namenda Xr | None | 22 | $9,259 | $421 |
| Carbidopa-Levodopa Er | None | 132 | $8,821 | $67 |
| Norco | None | 11 | $8,656 | $787 |
| Zohydro Er | None | 14 | $8,166 | $583 |
| Amantadine | None | 31 | $7,933 | $256 |
| Opana Er | None | 11 | $7,373 | $670 |
| Movantik | None | 22 | $7,043 | $320 |
| Xtampza Er | None | 12 | $6,936 | $578 |
| Exelon | None | 11 | $6,651 | $605 |
| Embeda | None | 13 | $6,249 | $481 |
| Rivastigmine | None | 22 | $6,105 | $277 |
| Levetiracetam | None | 175 | $6,082 | $35 |
| Morphine Sulfate Er | None | 70 | $5,837 | $83 |
| Carbidopa-Levodopa | None | 189 | $5,629 | $30 |
| Hydrocodone-Acetaminophen | None | 237 | $5,118 | $22 |
| Duloxetine | None | 84 | $5,111 | $61 |
| Gabapentin | None | 292 | $4,849 | $17 |
| Fentanyl | None | 33 | $4,152 | $126 |
| Lidocaine | None | 21 | $4,114 | $196 |
| Divalproex Sodium Er | None | 37 | $3,936 | $106 |
| Voltaren | None | 22 | $3,734 | $170 |
| Memantine | None | 57 | $2,867 | $50 |
| Carbamazepine Er | None | 12 | $2,852 | $238 |
| Oxycodone | None | 66 | $2,792 | $42 |
| Tizanidine | None | 85 | $2,513 | $30 |
| Ethosuximide | None | 12 | $2,467 | $206 |
| Donepezil | None | 128 | $2,286 | $18 |
| Tolterodine Tartrate Er | None | 13 | $2,120 | $163 |
| Phenobarbital | None | 49 | $2,087 | $43 |
| Midodrine | None | 22 | $1,909 | $87 |
| Oxycodone-Acetaminophen | None | 41 | $1,879 | $46 |
| Celecoxib | None | 26 | $1,758 | $68 |
| Zolpidem Tartrate Er | None | 12 | $1,505 | $125 |
| Divalproex | None | 46 | $1,489 | $32 |
| Oxcarbazepine | None | 22 | $1,480 | $67 |
| Quetiapine | None | 92 | $1,420 | $15 |
| Clorazepate Dipotassium | None | 11 | $1,318 | $120 |
| Topiramate | None | 69 | $1,298 | $19 |
| Baclofen | None | 35 | $1,199 | $34 |
| Pyridostigmine | None | 12 | $1,192 | $99 |
| Pramipexole Dihydrochloride | None | 49 | $1,142 | $23 |
| Propranolol | None | 57 | $1,070 | $19 |
| Carbamazepine | None | 11 | $966 | $88 |
| Ropinirole | None | 18 | $921 | $51 |
| Methylphenidate | None | 20 | $854 | $43 |
| Phenytoin Sodium Extended | None | 22 | $852 | $39 |
| Galantamine Hbr | None | 18 | $848 | $47 |
| Clopidogrel | None | 71 | $841 | $12 |
| Lamotrigine | None | 47 | $810 | $17 |
| Phenytoin | None | 12 | $802 | $67 |
| Primidone | None | 33 | $768 | $23 |
| Zonisamide | None | 33 | $761 | $23 |
| Bupropion Xl | None | 16 | $751 | $47 |
| Hydromorphone | None | 24 | $712 | $30 |
| Clonazepam | None | 99 | $711 | $7 |
| Cyclobenzaprine | None | 52 | $638 | $12 |
| Azathioprine | None | 19 | $612 | $32 |
| Tramadol | None | 73 | $499 | $7 |
| Citalopram Hbr | None | 82 | $468 | $6 |
| Escitalopram | None | 49 | $408 | $8 |
| Fludrocortisone Acetate | None | 19 | $400 | $21 |
| Amitriptyline | None | 21 | $400 | $19 |
| Rizatriptan | None | 16 | $391 | $24 |
| Bupropion Hcl Sr | None | 22 | $389 | $18 |
| Methadone | None | 17 | $376 | $22 |
| Diazepam | None | 47 | $357 | $8 |
| Morphine Sulfate | None | 19 | $346 | $18 |
| Sumatriptan | None | 12 | $301 | $25 |
| Sertraline | None | 24 | $295 | $12 |
| Atorvastatin | None | 14 | $281 | $20 |
| Alprazolam | None | 59 | $278 | $5 |
| Lorazepam | None | 58 | $237 | $4 |
| Acetaminophen-Codeine | None | 15 | $234 | $16 |
| Nortriptyline | None | 18 | $201 | $11 |
| Zolpidem | None | 55 | $175 | $3 |
| Carisoprodol | None | 27 | $169 | $6 |
| Venlafaxine Hcl Er | None | 22 | $158 | $7 |
| Amlodipine Besylate | None | 18 | $130 | $7 |
| Trazodone | None | 17 | $97 | $6 |
| Omeprazole | None | 17 | $90 | $5 |
| Meloxicam | None | 22 | $88 | $4 |
| Metoprolol | None | 12 | $87 | $7 |
| Buspirone | None | 12 | $60 | $5 |
| Famotidine | None | 11 | $22 | $2 |
2016: 108 drugs
| H.P. Acthar | None | 21 | $729,843 | $34,754 |
| Xenazine | None | 14 | $241,917 | $17,280 |
| Gamunex-C | Immune globulin | 26 | $170,828 | $6,570 |
| Vimpat | None | 157 | $112,722 | $718 |
| Copaxone | None | 14 | $95,639 | $6,831 |
| Privigen | Immune globulin | 20 | $61,065 | $3,053 |
| Lyrica | None | 94 | $53,211 | $566 |
| Azilect | None | 63 | $48,363 | $768 |
| Butrans | None | 91 | $45,358 | $498 |
| Keppra | None | 12 | $40,023 | $3,335 |
| Oxycontin | None | 44 | $31,060 | $706 |
| Aptiom | None | 17 | $27,349 | $1,609 |
| Neupro | None | 35 | $24,379 | $697 |
| Nuedexta | None | 30 | $24,322 | $811 |
| Namenda Xr | None | 61 | $23,963 | $393 |
| Rytary | Parkinson's | 61 | $18,338 | $301 |
| Nucynta | None | 17 | $18,043 | $1,061 |
| Opana Er | None | 25 | $16,784 | $671 |
| Fycompa | None | 23 | $15,055 | $655 |
| Lidocaine | None | 29 | $14,847 | $512 |
| Seroquel Xr | None | 20 | $14,301 | $715 |
| Namzaric | None | 36 | $13,850 | $385 |
| Keppra Xr | None | 15 | $11,885 | $792 |
| Oxymorphone Hcl Er | None | 24 | $11,603 | $483 |
| Onfi | None | 13 | $11,361 | $874 |
| Hydrocodone-Acetaminophen | None | 313 | $10,955 | $35 |
| Aripiprazole | None | 37 | $10,697 | $289 |
| Levetiracetam | None | 262 | $9,771 | $37 |
| Pyridostigmine Bromide Er | None | 14 | $9,060 | $647 |
| Exelon | None | 16 | $8,206 | $513 |
| Carbidopa-Levodopa Er | None | 166 | $7,752 | $47 |
| Norco | None | 11 | $7,582 | $689 |
| Gabapentin | None | 358 | $7,044 | $20 |
| Carbidopa-Levodopa | None | 241 | $6,685 | $28 |
| Divalproex Sodium Er | None | 49 | $6,501 | $133 |
| Morphine Sulfate Er | None | 61 | $5,947 | $97 |
| Amantadine | None | 35 | $5,578 | $159 |
| Carbidopa-Levodopa-Entacapone | None | 16 | $5,204 | $325 |
| Modafinil | None | 16 | $4,576 | $286 |
| Carbamazepine Er | None | 15 | $4,224 | $282 |
| Oxycodone | None | 84 | $3,961 | $47 |
| Memantine | None | 58 | $3,924 | $68 |
| Oxycodone-Acetaminophen | None | 62 | $3,805 | $61 |
| Carbamazepine | None | 48 | $3,789 | $79 |
| Duloxetine | None | 64 | $3,705 | $58 |
| Phenobarbital | None | 61 | $3,227 | $53 |
| Fentanyl | None | 34 | $3,077 | $90 |
| Viibryd | None | 14 | $2,957 | $211 |
| Mycophenolate Mofetil | None | 31 | $2,596 | $84 |
| Amitiza | None | 14 | $2,342 | $167 |
| Celecoxib | None | 19 | $2,297 | $121 |
| Voltaren | None | 16 | $2,094 | $131 |
| Tizanidine | None | 73 | $1,874 | $26 |
| Ethosuximide | None | 12 | $1,871 | $156 |
| Tegretol | None | 12 | $1,835 | $153 |
| Divalproex | None | 53 | $1,770 | $33 |
| Pramipexole Dihydrochloride | None | 46 | $1,640 | $36 |
| Donepezil | None | 138 | $1,615 | $12 |
| Baclofen | None | 77 | $1,609 | $21 |
| Topiramate | None | 110 | $1,597 | $15 |
| Midodrine | None | 25 | $1,535 | $61 |
| Phenytoin Sodium Extended | None | 28 | $1,488 | $53 |
| Lamotrigine | None | 72 | $1,470 | $20 |
| Clopidogrel | None | 113 | $1,376 | $12 |
| Quetiapine | None | 76 | $1,370 | $18 |
| Zonisamide | None | 54 | $1,364 | $25 |
| Pyridostigmine | None | 18 | $1,356 | $75 |
| Propranolol | None | 44 | $1,065 | $24 |
| Mirtazapine | None | 16 | $1,029 | $64 |
| Oxcarbazepine | None | 15 | $976 | $65 |
| Bupropion Xl | None | 15 | $966 | $64 |
| Primidone | None | 43 | $957 | $22 |
| Ropinirole | None | 18 | $824 | $46 |
| Morphine Sulfate | None | 34 | $749 | $22 |
| Methadone | None | 22 | $722 | $33 |
| Galantamine Hbr | None | 11 | $663 | $60 |
| Tramadol | None | 86 | $656 | $8 |
| Clonazepam | None | 107 | $633 | $6 |
| Methylphenidate | None | 17 | $621 | $37 |
| Citalopram Hbr | None | 93 | $516 | $6 |
| Orphenadrine Citrate | None | 13 | $489 | $38 |
| Escitalopram | None | 50 | $465 | $9 |
| Hydromorphone | None | 11 | $448 | $41 |
| Carisoprodol | None | 46 | $438 | $10 |
| Alprazolam | None | 67 | $433 | $6 |
| Atorvastatin | None | 12 | $425 | $35 |
| Acetaminophen-Codeine | None | 20 | $425 | $21 |
| Diazepam | None | 70 | $423 | $6 |
| Zolpidem | None | 87 | $413 | $5 |
| Bupropion Hcl Sr | None | 17 | $359 | $21 |
| Fludrocortisone Acetate | None | 22 | $354 | $16 |
| Lidocaine | None | 12 | $352 | $29 |
| Amitriptyline | None | 14 | $332 | $24 |
| Sumatriptan | None | 33 | $330 | $10 |
| Meloxicam | None | 19 | $320 | $17 |
| Metoprolol | None | 12 | $264 | $22 |
| Lorazepam | None | 52 | $234 | $5 |
| Nortriptyline | None | 19 | $212 | $11 |
| Ibuprofen | None | 42 | $204 | $5 |
| Cyclobenzaprine | None | 40 | $200 | $5 |
| Venlafaxine Hcl Er | None | 11 | $171 | $16 |
| Amlodipine Besylate | None | 30 | $110 | $4 |
| Trazodone | None | 19 | $109 | $6 |
| Sertraline | None | 18 | $95 | $5 |
| Fluoxetine | None | 11 | $88 | $8 |
| Paroxetine | None | 19 | $87 | $5 |
| Lisinopril | None | 12 | $80 | $7 |
| Omeprazole | None | 11 | $45 | $4 |
2015: 114 drugs
| H.P. Acthar | None | 21 | $703,813 | $33,515 |
| Xenazine | None | 23 | $260,574 | $11,329 |
| Gamunex-C | Immune globulin | 25 | $139,195 | $5,568 |
| Copaxone | None | 26 | $129,808 | $4,993 |
| Privigen | Immune globulin | 30 | $119,766 | $3,992 |
| Vimpat | None | 157 | $118,329 | $754 |
| Aubagio | None | 12 | $72,682 | $6,057 |
| Tecfidera | None | 11 | $60,778 | $5,525 |
| Azilect | None | 72 | $51,319 | $713 |
| Lyrica | None | 100 | $41,880 | $419 |
| Ampyra | None | 20 | $40,148 | $2,007 |
| Aptiom | None | 23 | $39,243 | $1,706 |
| Exelon | None | 66 | $32,372 | $490 |
| Namenda Xr | None | 83 | $30,719 | $370 |
| Keppra Xr | None | 30 | $29,150 | $972 |
| Oxycontin | None | 46 | $24,250 | $527 |
| Abilify | None | 16 | $20,625 | $1,289 |
| Butrans | None | 40 | $18,172 | $454 |
| Hydrocodone-Acetaminophen | None | 454 | $17,895 | $39 |
| Carbidopa-Levodopa-Entacapone | None | 28 | $17,554 | $627 |
| Neupro | None | 31 | $17,514 | $565 |
| Lidocaine | None | 43 | $16,096 | $374 |
| Nucynta | None | 17 | $15,734 | $926 |
| Morphine Sulfate Er | None | 108 | $14,369 | $133 |
| Nuedexta | None | 19 | $13,248 | $697 |
| Opana Er | None | 23 | $13,225 | $575 |
| Amantadine | None | 78 | $13,158 | $169 |
| Neurontin | None | 12 | $13,024 | $1,085 |
| Namenda | None | 34 | $12,489 | $367 |
| Divalproex Sodium Er | None | 67 | $11,813 | $176 |
| Levetiracetam | None | 320 | $11,090 | $35 |
| Oxymorphone Hcl Er | None | 26 | $10,605 | $408 |
| Effexor Xr | None | 12 | $10,224 | $852 |
| Carbidopa-Levodopa | None | 334 | $9,583 | $29 |
| Gabapentin | None | 497 | $9,090 | $18 |
| Duloxetine | None | 83 | $8,561 | $103 |
| Seroquel Xr | None | 13 | $8,220 | $632 |
| Celecoxib | None | 52 | $8,155 | $157 |
| Aripiprazole | None | 13 | $8,095 | $623 |
| Carbidopa-Levodopa Er | None | 135 | $8,018 | $59 |
| Fentanyl | None | 54 | $6,931 | $128 |
| Oxtellar Xr | None | 20 | $6,874 | $344 |
| Aggrenox | None | 14 | $6,671 | $476 |
| Lidoderm | None | 16 | $6,457 | $404 |
| Carbamazepine Er | None | 42 | $6,094 | $145 |
| Carbamazepine | None | 46 | $5,972 | $130 |
| Amitiza | None | 20 | $5,051 | $253 |
| Oxycodone | None | 85 | $5,041 | $59 |
| Oxycodone-Acetaminophen | None | 56 | $5,019 | $90 |
| Donepezil | None | 147 | $3,900 | $27 |
| Linzess | None | 12 | $3,458 | $288 |
| Rytary | Parkinson's | 14 | $3,094 | $221 |
| Phenytoin Sodium Extended | None | 69 | $2,948 | $43 |
| Pyridostigmine | None | 29 | $2,866 | $99 |
| Voltaren | None | 36 | $2,569 | $71 |
| Tizanidine | None | 73 | $2,483 | $34 |
| Baclofen | None | 87 | $2,382 | $27 |
| Viibryd | None | 11 | $2,155 | $196 |
| Topiramate | None | 163 | $2,106 | $13 |
| Carisoprodol | None | 125 | $2,052 | $16 |
| Clopidogrel | None | 105 | $1,894 | $18 |
| Ethosuximide | None | 12 | $1,868 | $156 |
| Phenobarbital | None | 51 | $1,782 | $35 |
| Methadone | None | 41 | $1,756 | $43 |
| Primidone | None | 74 | $1,633 | $22 |
| Lamotrigine | None | 84 | $1,631 | $19 |
| Galantamine Hbr | None | 25 | $1,614 | $65 |
| Midodrine | None | 18 | $1,605 | $89 |
| Codeine Sulfate | None | 11 | $1,531 | $139 |
| Zonisamide | None | 60 | $1,466 | $24 |
| Pramipexole Dihydrochloride | None | 39 | $1,269 | $33 |
| Morphine Sulfate | None | 62 | $1,194 | $19 |
| Divalproex | None | 41 | $1,174 | $29 |
| Oxcarbazepine | None | 17 | $1,124 | $66 |
| Ropinirole | None | 22 | $1,106 | $50 |
| Tramadol | None | 105 | $1,071 | $10 |
| Water | None | 18 | $1,044 | $58 |
| Bupropion Xl | None | 20 | $892 | $45 |
| Methylphenidate | None | 20 | $872 | $44 |
| Memantine | None | 13 | $833 | $64 |
| Epitol | None | 13 | $823 | $63 |
| Diazepam | None | 97 | $754 | $8 |
| Quetiapine | None | 59 | $702 | $12 |
| Metoprolol | None | 14 | $678 | $48 |
| Clonazepam | None | 115 | $671 | $6 |
| Propranolol | None | 52 | $627 | $12 |
| Atorvastatin | None | 16 | $623 | $39 |
| Sumatriptan | None | 32 | $603 | $19 |
| Alprazolam | None | 93 | $485 | $5 |
| Hydromorphone | None | 14 | $482 | $34 |
| Cyclobenzaprine | None | 47 | $473 | $10 |
| Escitalopram | None | 47 | $469 | $10 |
| Zolpidem | None | 65 | $455 | $7 |
| Orphenadrine Citrate | None | 11 | $448 | $41 |
| Lorazepam | None | 63 | $434 | $7 |
| Nabumetone | None | 13 | $429 | $33 |
| Phenytoin | None | 13 | $419 | $32 |
| Acetaminophen-Codeine | None | 25 | $403 | $16 |
| Citalopram Hbr | None | 62 | $384 | $6 |
| Benztropine Mesylate | None | 18 | $357 | $20 |
| Nortriptyline | None | 50 | $339 | $7 |
| Bupropion Hcl Sr | None | 18 | $277 | $15 |
| Meloxicam | None | 19 | $201 | $11 |
| Fluoxetine | None | 24 | $171 | $7 |
| Risperidone | None | 16 | $148 | $9 |
| Prochlorperazine Maleate | None | 21 | $142 | $7 |
| Trazodone | None | 31 | $141 | $5 |
| Paroxetine | None | 21 | $141 | $7 |
| Ibuprofen | None | 22 | $117 | $5 |
| Metformin | None | 15 | $112 | $7 |
| Amlodipine Besylate | None | 21 | $95 | $5 |
| Omeprazole | None | 21 | $95 | $5 |
| Lisinopril | None | 18 | $94 | $5 |
| Prednisone | None | 11 | $42 | $4 |
2014: 109 drugs
| H.P. Acthar | None | 25 | $809,889 | $32,396 |
| Copaxone | None | 33 | $160,200 | $4,855 |
| Xenazine | None | 11 | $111,878 | $10,171 |
| Gamunex-C | Immune globulin | 15 | $108,642 | $7,243 |
| Vimpat | None | 128 | $89,282 | $698 |
| Privigen | Immune globulin | 25 | $87,618 | $3,505 |
| Gilenya | None | 13 | $66,979 | $5,152 |
| Aubagio | None | 13 | $61,232 | $4,710 |
| Betaseron | None | 12 | $59,605 | $4,967 |
| Avonex | None | 12 | $55,917 | $4,660 |
| Azilect | None | 88 | $54,241 | $616 |
| Lyrica | None | 145 | $48,691 | $336 |
| Keppra Xr | None | 41 | $41,139 | $1,003 |
| Exelon | None | 90 | $36,423 | $405 |
| Ampyra | None | 20 | $32,667 | $1,633 |
| Abilify | None | 37 | $32,305 | $873 |
| Banzel | None | 11 | $31,658 | $2,878 |
| Oxycontin | None | 56 | $29,205 | $522 |
| Namenda | None | 80 | $27,807 | $348 |
| Carbidopa-Levodopa-Entacapone | None | 50 | $26,714 | $534 |
| Duloxetine | None | 102 | $21,408 | $210 |
| Lidoderm | None | 44 | $19,069 | $433 |
| Hydrocodone-Acetaminophen | None | 545 | $18,930 | $35 |
| Levetiracetam | None | 360 | $17,177 | $48 |
| Celebrex | None | 51 | $15,455 | $303 |
| Morphine Sulfate Er | None | 104 | $14,897 | $143 |
| Butrans | None | 32 | $14,095 | $440 |
| Lidocaine | None | 34 | $13,883 | $408 |
| Divalproex Sodium Er | None | 74 | $13,396 | $181 |
| Nuedexta | None | 16 | $10,486 | $655 |
| Seroquel Xr | None | 13 | $9,831 | $756 |
| Amantadine | None | 59 | $8,996 | $152 |
| Fentanyl | None | 50 | $8,973 | $179 |
| Gabapentin | None | 497 | $8,964 | $18 |
| Carbidopa-Levodopa | None | 257 | $8,506 | $33 |
| Nucynta | None | 20 | $8,311 | $416 |
| Aggrenox | None | 19 | $7,596 | $400 |
| Namenda Xr | None | 21 | $7,020 | $334 |
| Oxycodone-Acetaminophen | None | 59 | $5,612 | $95 |
| Norco | None | 11 | $5,412 | $492 |
| Oxymorphone Hcl Er | None | 13 | $5,392 | $415 |
| Carbidopa-Levodopa Er | None | 98 | $5,329 | $54 |
| Oxycodone | None | 81 | $5,309 | $66 |
| Opana Er | None | 12 | $5,300 | $442 |
| Carbamazepine | None | 61 | $5,215 | $85 |
| Metaxalone | None | 12 | $5,130 | $428 |
| Amitiza | None | 18 | $3,997 | $222 |
| Carisoprodol | None | 135 | $3,810 | $28 |
| Donepezil | None | 100 | $3,791 | $38 |
| Oxtellar Xr | None | 12 | $3,180 | $265 |
| Viibryd | None | 14 | $3,117 | $223 |
| Voltaren | None | 22 | $3,036 | $138 |
| Tizanidine | None | 77 | $2,877 | $37 |
| Galantamine Hbr | None | 43 | $2,699 | $63 |
| Carbamazepine Xr | None | 11 | $2,669 | $243 |
| Pramipexole Dihydrochloride | None | 40 | $2,623 | $66 |
| Ropinirole | None | 50 | $2,606 | $52 |
| Topiramate | None | 169 | $2,605 | $15 |
| Zonisamide | None | 50 | $2,443 | $49 |
| Quetiapine | None | 68 | $2,335 | $34 |
| Primidone | None | 69 | $2,007 | $29 |
| Diovan | None | 12 | $1,960 | $163 |
| Lamotrigine | None | 109 | $1,722 | $16 |
| Phenytoin Sodium Extended | None | 73 | $1,706 | $23 |
| Pyridostigmine | None | 25 | $1,686 | $67 |
| Clopidogrel | None | 70 | $1,612 | $23 |
| Baclofen | None | 88 | $1,441 | $16 |
| Tramadol | None | 99 | $1,321 | $13 |
| Bupropion Xl | None | 37 | $1,307 | $35 |
| Phenobarbital | None | 86 | $1,264 | $15 |
| Paroxetine | None | 25 | $1,236 | $49 |
| Morphine Sulfate | None | 70 | $1,172 | $17 |
| Methylphenidate | None | 17 | $1,042 | $61 |
| Novolin 70-30 | None | 11 | $1,020 | $93 |
| Lansoprazole | None | 16 | $980 | $61 |
| Sumatriptan | None | 49 | $977 | $20 |
| Methadone | None | 37 | $904 | $24 |
| Hydromorphone | None | 15 | $796 | $53 |
| Diazepam | None | 123 | $768 | $6 |
| Cyclobenzaprine | None | 15 | $707 | $47 |
| Clonazepam | None | 109 | $683 | $6 |
| Divalproex | None | 22 | $659 | $30 |
| Lorazepam | None | 81 | $610 | $8 |
| Alprazolam | None | 95 | $577 | $6 |
| Oxcarbazepine | None | 12 | $542 | $45 |
| Zolpidem | None | 54 | $461 | $9 |
| Escitalopram | None | 33 | $424 | $13 |
| Bupropion Hcl Sr | None | 19 | $404 | $21 |
| Risperidone | None | 37 | $387 | $10 |
| Citalopram Hbr | None | 42 | $386 | $9 |
| Nortriptyline | None | 33 | $376 | $11 |
| Nabumetone | None | 14 | $359 | $26 |
| Acetaminophen-Codeine | None | 22 | $358 | $16 |
| Benztropine Mesylate | None | 13 | $357 | $27 |
| Isosorbide Mononitrate Er | None | 15 | $345 | $23 |
| Meloxicam | None | 27 | $327 | $12 |
| Metoprolol | None | 12 | $325 | $27 |
| Omeprazole | None | 29 | $245 | $8 |
| Propranolol | None | 37 | $235 | $6 |
| Lisinopril | None | 28 | $190 | $7 |
| Trazodone | None | 29 | $172 | $6 |
| Fluoxetine | None | 12 | $161 | $13 |
| Trihexyphenidyl | None | 12 | $124 | $10 |
| Ibuprofen | None | 18 | $115 | $6 |
| Metformin | None | 17 | $100 | $6 |
| Amlodipine Besylate | None | 19 | $93 | $5 |
| Hydroxyzine Pamoate | None | 11 | $81 | $7 |
| Amitriptyline | None | 18 | $63 | $3 |
| Atenolol | None | 12 | $48 | $4 |
2013: 102 drugs
| Gamunex-C | Immune globulin | 20 | $145,589 | $7,279 |
| Xenazine | None | 26 | $143,447 | $5,517 |
| Vimpat | None | 174 | $105,563 | $607 |
| Copaxone | None | 15 | $71,613 | $4,774 |
| Gilenya | None | 13 | $61,898 | $4,761 |
| Oxycontin | None | 90 | $56,611 | $629 |
| Lyrica | None | 192 | $53,430 | $278 |
| Betaseron | None | 12 | $51,718 | $4,310 |
| Avonex | None | 12 | $50,136 | $4,178 |
| Rebif | None | 12 | $49,284 | $4,107 |
| Ampyra | None | 25 | $36,644 | $1,466 |
| Exelon | None | 110 | $36,126 | $328 |
| Exalgo | None | 24 | $35,508 | $1,479 |
| Cymbalta | None | 83 | $33,964 | $409 |
| Namenda | None | 110 | $32,018 | $291 |
| Azilect | None | 54 | $30,981 | $574 |
| Keppra Xr | None | 33 | $30,287 | $918 |
| Abilify | None | 42 | $29,093 | $693 |
| Carbidopa-Levodopa-Entacapone | None | 60 | $28,727 | $479 |
| Levetiracetam | None | 417 | $23,729 | $57 |
| Lidoderm | None | 49 | $21,365 | $436 |
| Hydrocodone-Acetaminophen | None | 663 | $18,307 | $28 |
| Keppra | None | 25 | $14,256 | $570 |
| Fentanyl | None | 50 | $10,918 | $218 |
| Carbidopa-Levodopa | None | 293 | $9,844 | $34 |
| Gabapentin | None | 456 | $9,552 | $21 |
| Morphine Sulfate Er | None | 85 | $9,437 | $111 |
| Quetiapine | None | 57 | $7,975 | $140 |
| Butrans | None | 19 | $7,755 | $408 |
| Celebrex | None | 43 | $7,619 | $177 |
| Nucynta | None | 18 | $7,329 | $407 |
| Divalproex Sodium Er | None | 61 | $6,444 | $106 |
| Seroquel Xr | None | 11 | $5,951 | $541 |
| Amantadine | None | 45 | $5,916 | $131 |
| Opana Er | None | 14 | $5,639 | $403 |
| Aggrenox | None | 20 | $5,445 | $272 |
| Pristiq Er | None | 31 | $5,375 | $173 |
| Pramipexole Dihydrochloride | None | 64 | $5,271 | $82 |
| Metaxalone | None | 12 | $5,122 | $427 |
| Oxycodone Hcl-Acetaminophen | None | 77 | $4,865 | $63 |
| Carbidopa-Levodopa Er | None | 94 | $4,859 | $52 |
| Clopidogrel | None | 115 | $4,682 | $41 |
| Oxycodone | None | 80 | $4,493 | $56 |
| Aricept | None | 14 | $4,331 | $309 |
| Carbamazepine | None | 60 | $3,381 | $56 |
| Topiramate | None | 169 | $3,254 | $19 |
| Amitiza | None | 13 | $3,230 | $248 |
| Lamotrigine | None | 129 | $3,167 | $25 |
| Voltaren | None | 24 | $2,888 | $120 |
| Zonisamide | None | 59 | $2,886 | $49 |
| Escitalopram | None | 39 | $2,718 | $70 |
| Carisoprodol | None | 162 | $2,644 | $16 |
| Diovan | None | 14 | $2,521 | $180 |
| Primidone | None | 65 | $2,463 | $38 |
| Ropinirole | None | 51 | $2,372 | $47 |
| Tizanidine | None | 78 | $2,291 | $29 |
| Viibryd | None | 13 | $2,219 | $171 |
| Phenytoin Sodium Extended | None | 88 | $1,949 | $22 |
| Gralise | None | 12 | $1,888 | $157 |
| Phenytek | None | 26 | $1,852 | $71 |
| Paroxetine | None | 49 | $1,628 | $33 |
| Tramadol | None | 94 | $1,614 | $17 |
| Sumatriptan | None | 52 | $1,441 | $28 |
| Methadone | None | 41 | $1,407 | $34 |
| Baclofen | None | 96 | $1,244 | $13 |
| Phenobarbital | None | 81 | $1,241 | $15 |
| Donepezil | None | 64 | $1,206 | $19 |
| Bupropion Xl | None | 27 | $1,025 | $38 |
| Clonazepam | None | 117 | $1,018 | $9 |
| Hydromorphone | None | 17 | $943 | $55 |
| Morphine Sulfate | None | 50 | $933 | $19 |
| Lorazepam | None | 102 | $815 | $8 |
| Atorvastatin | None | 22 | $709 | $32 |
| Alprazolam | None | 94 | $657 | $7 |
| Venlafaxine Hcl Er | None | 18 | $624 | $35 |
| Diazepam | None | 83 | $616 | $7 |
| Citalopram Hbr | None | 55 | $611 | $11 |
| Methylphenidate | None | 21 | $583 | $28 |
| Divalproex | None | 18 | $544 | $30 |
| Tramadol Hcl-Acetaminophen | None | 17 | $516 | $30 |
| Acetaminophen-Codeine | None | 28 | $426 | $15 |
| Fluoxetine | None | 27 | $416 | $15 |
| Nortriptyline | None | 38 | $328 | $9 |
| Propranolol | None | 46 | $296 | $6 |
| Prednisone | None | 25 | $271 | $11 |
| Nabumetone | None | 13 | $250 | $19 |
| Ibuprofen | None | 30 | $247 | $8 |
| Trazodone | None | 33 | $220 | $7 |
| Benztropine Mesylate | None | 11 | $205 | $19 |
| Risperidone | None | 15 | $191 | $13 |
| Omeprazole | None | 21 | $189 | $9 |
| Mirtazapine | None | 11 | $187 | $17 |
| Hydroxyzine Pamoate | None | 16 | $163 | $10 |
| Zolpidem | None | 25 | $159 | $6 |
| Trihexyphenidyl | None | 26 | $156 | $6 |
| Lisinopril | None | 20 | $133 | $7 |
| Temazepam | None | 13 | $123 | $9 |
| Cyclobenzaprine | None | 12 | $107 | $9 |
| Meloxicam | None | 17 | $89 | $5 |
| Losartan | None | 12 | $67 | $6 |
| Benazepril | None | 12 | $64 | $5 |
| Hydrochlorothiazide | None | 16 | $59 | $4 |
Money from drug and device companies
$82,629 in 2025
| 2025 | 46 | 328 | $71,471 | $82,629 |
| 2024 | 45 | 308 | $61,444 | $77,401 |
| 2023 | 46 | 275 | $19,222 | $29,586 |
| 2022 | 50 | 295 | $15,338 | $22,569 |
| 2021 | 51 | 314 | $15,242 | $21,333 |
| 2020 | 45 | 222 | $21,030 | $28,199 |
| 2019 | 41 | 211 | $11,365 | $17,503 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lilly USA | Kisunla | $17,958 | 17 payments
|
| Eisai | Leqembi | $14,489 | 28 payments
|
| Axsome Therapeutics | Symbravo | $14,332 | 22 payments
|
| Abbvie | Qulipta | $14,176 | 42 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $12,337 | 17 payments
|
| Otsuka America Pharmaceutical | Rexulti | $3,881 | 4 payments
|
See all 327 published payments
| Cycle Pharmaceuticals | Meals · 2025-12-29 | Bafiertam | $26 |
| Eisai | Consulting · 2025-12-26 | Leqembi | $110 |
| Axsome Therapeutics | Meals · 2025-12-20 | Symbravo | $23 |
| Axsome Therapeutics | Honoraria · 2025-12-19 | Symbravo | $2,025 |
| SK Life Science | Meals · 2025-12-19 | None | $31 |
| Axsome Therapeutics | Meals · 2025-12-18 | Symbravo | $34 |
| Axsome Therapeutics | Honoraria · 2025-12-18 | Symbravo | $2,025 |
| ANI Pharmaceuticals | Meals · 2025-12-18 | Purified Cortrophin Gel | $8 |
| ANI Pharmaceuticals | Meals · 2025-12-18 | Purified Cortrophin Gel | $15 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-17 | Hyqvia | $29 |
| Ucb | Meals · 2025-12-17 | Fintepla | $18 |
| Abbvie | Meals · 2025-12-13 | Ubrelvy | $6 |
| Biogen | Meals · 2025-12-12 | Leqembi | $26 |
| Lilly USA | Paid to speak or teach · 2025-12-11 | Kisunla | $1,050 |
| Pfizer | Meals · 2025-12-10 | Nurtec Odt | $22 |
| Lilly USA | Paid to speak or teach · 2025-12-09 | Kisunla | $1,050 |
| SK Life Science | Meals · 2025-12-09 | None | $32 |
| Janssen Biotech | Meals · 2025-12-08 | None | $26 |
| Merz Pharmaceuticals | Meals · 2025-12-08 | Xeomin | $24 |
| Lilly USA | Paid to speak or teach · 2025-12-04 | Kisunla | $1,050 |
| Jazz Pharmaceuticals | Meals · 2025-12-04 | Epidiolex | $36 |
| Axsome Therapeutics | Meals · 2025-12-04 | Symbravo | $32 |
| Novartis Pharmaceuticals | Meals · 2025-12-03 | Kesimpta | $18 |
| Neurelis | Meals · 2025-12-03 | Valtoco | $26 |
| Teva Pharmaceuticals USA | Meals · 2025-12-02 | Austedo Xr | $29 |
| ACADIA Pharmaceuticals | Meals · 2025-12-02 | Nuplazid | $20 |
| Ucb | Meals · 2025-11-25 | Fintepla | $20 |
| Axsome Therapeutics | Meals · 2025-11-24 | Symbravo | $31 |
| Eisai | Meals · 2025-11-24 | Leqembi | $13 |
| Eisai | Consulting · 2025-11-13 | Leqembi | $1,600 |
| SK Life Science | Meals · 2025-11-11 | None | $34 |
| Argenx US | Meals · 2025-11-10 | Vyvgart | $31 |
| Axsome Therapeutics | Meals · 2025-11-06 | Symbravo | $27 |
| MDD US Operations | Meals · 2025-11-05 | Qelbree | $26 |
| Teva Pharmaceuticals USA | Meals · 2025-11-04 | Austedo Xr | $26 |
| Ucb | Meals · 2025-11-03 | Fintepla | $5 |
| Ucb | Meals · 2025-11-03 | Fintepla | $7 |
| Axsome Therapeutics | Meals · 2025-11-03 | Symbravo | $3 |
| Axsome Therapeutics | Meals · 2025-11-03 | Symbravo | $31 |
| Eisai | Meals · 2025-11-02 | Leqembi | $13 |
| Lilly USA | Paid to speak or teach · 2025-10-31 | Kisunla | $1,050 |
| Otsuka America Pharmaceutical | Paid to speak or teach · 2025-10-31 | Rexulti | $2,236 |
| Abbvie | Meals · 2025-10-30 | Ubrelvy | $5 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-30 | Relistor | $25 |
| ANI Pharmaceuticals | Meals · 2025-10-30 | Purified Cortrophin Gel | $29 |
| Lundbeck | Meals · 2025-10-30 | Vyepti | $32 |
| Alnylam Pharmaceuticals | Meals · 2025-10-28 | Amvuttra | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-10-28 | Rexulti | $123 |
| Alexion Pharmaceuticals | Meals · 2025-10-24 | Ultomiris | $33 |
| Pfizer | Meals · 2025-10-24 | Nurtec Odt | $26 |
| Ucb | Meals · 2025-10-22 | Nayzilam | $17 |
| SK Life Science | Meals · 2025-10-22 | None | $14 |
| TG Therapeutics | Meals · 2025-10-20 | Briumvi | $30 |
| Eisai | Meals · 2025-10-20 | Leqembi | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-16 | Hyqvia | $31 |
| Lilly USA | Paid to speak or teach · 2025-10-15 | Kisunla | $1,050 |
| Neurelis | Meals · 2025-10-15 | Valtoco | $21 |
| MDD US Operations | Meals · 2025-10-15 | Qelbree | $26 |
| MDD US Operations | Meals · 2025-10-15 | Qelbree | $9 |
| MDD US Operations | Meals · 2025-10-15 | Qelbree | $6 |
| SK Life Science | Meals · 2025-10-14 | None | $26 |
| Octapharma USA | Meals · 2025-10-13 | Panzyga | $25 |
| Merz Pharmaceuticals | Meals · 2025-10-11 | Xeomin | $38 |
| Janssen Biotech | Meals · 2025-10-09 | None | $28 |
| Jazz Pharmaceuticals | Meals · 2025-10-09 | Epidiolex | $3 |
| Jazz Pharmaceuticals | Meals · 2025-10-09 | Epidiolex | $1 |
| ANI Pharmaceuticals | Meals · 2025-10-09 | Purified Cortrophin Gel | $22 |
| Genentech USA | Meals · 2025-10-08 | Ocrevus Zunovo | $29 |
| Jazz Pharmaceuticals | Meals · 2025-10-08 | Epidiolex | $12 |
| Amgen | Meals · 2025-10-06 | Uplizna | $23 |
| Teva Pharmaceuticals USA | Meals · 2025-10-06 | Austedo Xr | $14 |
| Axsome Therapeutics | Meals · 2025-10-04 | Symbravo | $34 |
| Abbvie | Paid to speak or teach · 2025-10-02 | Qulipta | $1,463 |
| Ucb | Meals · 2025-10-02 | Fintepla | $26 |
| Abbvie | Meals · 2025-10-01 | Ubrelvy | $14 |
| Argenx US | Meals · 2025-10-01 | Vyvgart | $25 |
| Neurelis | Meals · 2025-09-30 | Valtoco | $24 |
| Amgen | Meals · 2025-09-30 | Uplizna | $131 |
| Abbvie | Meals · 2025-09-29 | Vyalev | $29 |
| Jazz Pharmaceuticals | Meals · 2025-09-29 | Epidiolex | $35 |
| Lilly USA | Paid to speak or teach · 2025-09-26 | Kisunla | $1,050 |
| ANI Pharmaceuticals | Meals · 2025-09-25 | Purified Cortrophin Gel | $25 |
| Lilly USA | Meals · 2025-09-22 | Kisunla | $13 |
| Lilly USA | Travel · 2025-09-22 | Kisunla | $21 |
| Lilly USA | Meals · 2025-09-22 | Kisunla | $23 |
| Lilly USA | Travel · 2025-09-22 | Kisunla | $51 |
| Ucb | Meals · 2025-09-22 | Fintepla | $41 |
| Lilly USA | Paid to speak or teach · 2025-09-18 | Kisunla | $1,050 |
| Virtus Pharmaceuticals | Meals · 2025-09-18 | Levorphanol Tartrate | $107 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Kesimpta | $21 |
| Axsome Therapeutics | Meals · 2025-09-16 | Symbravo | $34 |
| Teva Pharmaceuticals USA | Meals · 2025-09-16 | Austedo Xr | $122 |
| Teva Pharmaceuticals USA | Paid to speak or teach · 2025-09-16 | Austedo Xr | $3,250 |
| Amgen | Meals · 2025-09-15 | Uplizna | $18 |
| Ge Healthcare | Meals · 2025-09-11 | None | $20 |
| Eisai | Travel · 2025-09-11 | Leqembi | $1,027 |
| Argenx US | Meals · 2025-09-10 | Vyvgart Hytrulo | $1 |
| Argenx US | Meals · 2025-09-10 | Vyvgart | $15 |
| Argenx US | Meals · 2025-09-10 | Vyvgart | $4 |
| Eisai | Meals · 2025-09-10 | Leqembi | $19 |
| Alexion Pharmaceuticals | Meals · 2025-09-09 | Ultomiris | $33 |
| Axsome Therapeutics | Honoraria · 2025-09-09 | Symbravo | $2,025 |
| Eisai | Paid to speak or teach · 2025-09-09 | Leqembi | $1,920 |
| Eisai | Meals · 2025-09-09 | Leqembi | $80 |
| Eisai | Paid to speak or teach · 2025-09-09 | Leqembi | $1,600 |
| Abbvie | Meals · 2025-09-08 | Botox | $23 |
| Ucb | Meals · 2025-09-04 | Fintepla | $43 |
| Lundbeck | Meals · 2025-09-04 | Vyepti | $24 |
| Janssen Biotech | Meals · 2025-09-02 | None | $14 |
| Lilly USA | Paid to speak or teach · 2025-08-28 | Kisunla | $5,250 |
| ANI Pharmaceuticals | Meals · 2025-08-28 | Purified Cortrophin Gel | $25 |
| Mallinckrodt Hospital Products | Meals · 2025-08-27 | Acthar | $32 |
| Eisai | Meals · 2025-08-26 | Leqembi | $25 |
| Abbvie | Meals · 2025-08-25 | Botox | $28 |
| Teva Pharmaceuticals USA | Consulting · 2025-08-25 | Austedo Xr | $705 |
| Axsome Therapeutics | Meals · 2025-08-22 | Symbravo | $32 |
| Genentech USA | Meals · 2025-08-21 | Ocrevus Zunovo | $27 |
| Ipsen Biopharmaceuticals | Meals · 2025-08-19 | Dysport | $17 |
| CSL Behring | Meals · 2025-08-19 | Hizentra | $20 |
| Ucb | Meals · 2025-08-18 | Fintepla | $32 |
| Axsome Therapeutics | Meals · 2025-08-16 | Symbravo | $30 |
| Axsome Therapeutics | Meals · 2025-08-15 | Symbravo | $18 |
| Eisai | Meals · 2025-08-13 | Leqembi | $15 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Kesimpta | $22 |
| Neurocrine BioSciences | Meals · 2025-08-12 | Ingrezza | $30 |
| Ucb | Meals · 2025-08-08 | Fintepla | $17 |
| Ucb | Meals · 2025-08-07 | Briviact | $21 |
| SK Life Science | Meals · 2025-08-06 | None | $28 |
| Axsome Therapeutics | Meals · 2025-08-05 | Auvelity | $11 |
| Abbvie | Meals · 2025-08-04 | Qulipta | $20 |
| Abbvie | Meals · 2025-08-02 | Ubrelvy | $6 |
| Alexion Pharmaceuticals | Meals · 2025-07-30 | Ultomiris | $27 |
| Alnylam Pharmaceuticals | Meals · 2025-07-29 | Amvuttra | $27 |
| EMD Serono | Meals · 2025-07-29 | None | $28 |
| Ucb | Meals · 2025-07-28 | Rystiggo | $46 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-24 | Hyqvia | $29 |
| Teva Pharmaceuticals USA | Meals · 2025-07-24 | Austedo Xr | $9 |
| ANI Pharmaceuticals | Meals · 2025-07-24 | Purified Cortrophin Gel | $20 |
| Janssen Scientific Affairs | Meals · 2025-07-23 | None | $14 |
| Mallinckrodt Hospital Products | Meals · 2025-07-22 | Acthar | $27 |
| Harmony Biosciences | Meals · 2025-07-22 | Wakix | $26 |
| Pfizer | Meals · 2025-07-21 | Nurtec Odt | $22 |
| Lilly USA | Paid to speak or teach · 2025-07-18 | Kisunla | $1,050 |
| Axsome Therapeutics | Honoraria · 2025-07-17 | Symbravo | $4,725 |
| SK Life Science | Meals · 2025-07-17 | None | $13 |
| Abbvie | Meals · 2025-07-16 | Ubrelvy | $9 |
| Biogen | Meals · 2025-07-16 | Vumerity | $14 |
| Axsome Therapeutics | Meals · 2025-07-16 | Symbravo | $22 |
| Axsome Therapeutics | Honoraria · 2025-07-16 | Symbravo | $3,038 |
| Axsome Therapeutics | Meals · 2025-07-16 | Symbravo | $98 |
| Ucb | Meals · 2025-07-14 | Fintepla | $24 |
| Novartis Pharmaceuticals | Meals · 2025-07-08 | Kesimpta | $19 |
| Axsome Therapeutics | Meals · 2025-07-01 | Symbravo | $18 |
| Abbvie | Meals · 2025-06-30 | Qulipta | $12 |
| Harmony Biosciences | Education · 2025-06-30 | None | $70 |
| Merz Pharmaceuticals | Meals · 2025-06-27 | Xeomin | $20 |
| Mallinckrodt Hospital Products | Meals · 2025-06-25 | Acthar | $21 |
| Neurelis | Meals · 2025-06-25 | Valtoco | $26 |
| Otsuka America Pharmaceutical | Paid to speak or teach · 2025-06-25 | Rexulti | $1,088 |
| Genzyme | Meals · 2025-06-24 | None | $17 |
| EMD Serono | Meals · 2025-06-24 | None | $45 |
| Abbvie | Meals · 2025-06-23 | Ubrelvy | $5 |
| Ucb | Meals · 2025-06-23 | Fintepla | $10 |
| Eisai | Paid to speak or teach · 2025-06-23 | Leqembi | $1,463 |
| Eisai | Meals · 2025-06-23 | Leqembi | $122 |
| Eisai | Paid to speak or teach · 2025-06-23 | Leqembi | $585 |
| Lilly USA | Paid to speak or teach · 2025-06-18 | Kisunla | $1,050 |
| Ucb | Meals · 2025-06-18 | Nayzilam | $35 |
| Alexion Pharmaceuticals | Meals · 2025-06-17 | Ultomiris | $27 |
| Argenx US | Meals · 2025-06-17 | Vyvgart | $22 |
| Teva Pharmaceuticals USA | Meals · 2025-06-17 | Austedo Xr | $15 |
| Lilly USA | Paid to speak or teach · 2025-06-12 | Kisunla | $1,050 |
| ANI Pharmaceuticals | Meals · 2025-06-12 | Purified Cortrophin Gel | $17 |
| Axsome Therapeutics | Meals · 2025-06-10 | Symbravo | $18 |
| Abbvie | Meals · 2025-06-09 | Ubrelvy | $8 |
| Ucb | Meals · 2025-06-06 | Rystiggo | $35 |
| Eisai | Meals · 2025-06-05 | Leqembi | $125 |
| Eisai | Paid to speak or teach · 2025-06-05 | Leqembi | $1,463 |
| Eisai | Paid to speak or teach · 2025-06-05 | Leqembi | $585 |
| Lundbeck | Meals · 2025-06-05 | Vyepti | $22 |
| Janssen Biotech | Meals · 2025-06-04 | None | $17 |
| Amgen | Meals · 2025-06-04 | Uplizna | $28 |
| MDD US Operations | Meals · 2025-06-04 | None | $36 |
| Neurocrine BioSciences | Meals · 2025-06-04 | Ingrezza | $24 |
| Abbvie | Meals · 2025-05-30 | Ubrelvy | $6 |
| Abbvie | Meals · 2025-05-23 | Ubrelvy | $5 |
| Neurocrine BioSciences | Meals · 2025-05-23 | Ingrezza | $2 |
| Aucta Pharmaceuticals | Meals · 2025-05-23 | Motpoly Xr | $27 |
| Neurelis | Meals · 2025-05-22 | Valtoco | $27 |
| Neurocrine BioSciences | Meals · 2025-05-22 | Ingrezza | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-21 | Kesimpta | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-21 | Kesimpta | $1 |
| Teva Pharmaceuticals USA | Meals · 2025-05-21 | Austedo Xr | $7 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-20 | Hyqvia | $20 |
| Abbvie | Paid to speak or teach · 2025-05-16 | Qulipta | $3,250 |
| EMD Serono | Meals · 2025-05-15 | None | $22 |
| Alexion Pharmaceuticals | Meals · 2025-05-14 | Ultomiris | $13 |
| Eisai | Meals · 2025-05-14 | Leqembi | $15 |
| Biogen | Meals · 2025-05-13 | Vumerity | $23 |
| Ucb | Meals · 2025-05-13 | Briviact | $28 |
| Eisai | Paid to speak or teach · 2025-05-13 | Leqembi | $1,463 |
| Eisai | Paid to speak or teach · 2025-05-13 | Leqembi | $585 |
| Eisai | Meals · 2025-05-13 | Leqembi | $125 |
| Abbvie | Travel · 2025-05-09 | None | $45 |
| Abbvie | Consulting · 2025-05-09 | None | $4,388 |
| Abbvie | Meals · 2025-05-09 | None | $50 |
| Eisai | Consulting · 2025-05-09 | Leqembi | $183 |
| Eisai | Consulting · 2025-05-09 | Leqembi | $110 |
| Genentech USA | Meals · 2025-05-08 | Ocrevus Zunovo | $20 |
| ANI Pharmaceuticals | Meals · 2025-05-08 | Purified Cortrophin Gel | $22 |
| Grifols USA | Meals · 2025-05-08 | Gamunex-C | $23 |
| Lilly USA | Paid to speak or teach · 2025-05-06 | Kisunla | $1,050 |
| Ucb | Meals · 2025-05-06 | Rystiggo | $41 |
| Teva Pharmaceuticals USA | Meals · 2025-05-06 | Austedo Xr | $125 |
| Teva Pharmaceuticals USA | Travel · 2025-05-06 | Austedo Xr | $1,089 |
| Teva Pharmaceuticals USA | Paid to speak or teach · 2025-05-06 | Austedo Xr | $4,876 |
| Alexion Pharmaceuticals | Meals · 2025-05-05 | Ultomiris | $30 |
| Celgene | Meals · 2025-05-02 | Zeposia | $23 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Kesimpta | $10 |
| Abbvie | Meals · 2025-05-01 | Qulipta | $125 |
| Amgen | Meals · 2025-04-30 | Uplizna | $16 |
| ANI Pharmaceuticals | Meals · 2025-04-30 | Purified Cortrophin Gel | $8 |
| Abbvie | Meals · 2025-04-29 | Ubrelvy | $8 |
| Lilly USA | Paid to speak or teach · 2025-04-28 | Kisunla | $1,050 |
| Pfizer | Meals · 2025-04-28 | Nurtec Odt | $17 |
| Celgene | Meals · 2025-04-25 | Zeposia | $16 |
| Argenx US | Meals · 2025-04-24 | Vyvgart | $30 |
| Teva Pharmaceuticals USA | Paid to speak or teach · 2025-04-23 | Austedo Xr | $2,008 |
| Mallinckrodt Hospital Products | Meals · 2025-04-22 | Acthar | $19 |
| Teva Pharmaceuticals USA | Meals · 2025-04-22 | Austedo Xr | $12 |
| Otsuka America Pharmaceutical | Paid to speak or teach · 2025-04-18 | Rexulti | $435 |
| Neurelis | Meals · 2025-04-17 | Valtoco | $20 |
| CSL Behring | Meals · 2025-04-17 | Hizentra | $18 |
| Eisai | Meals · 2025-04-17 | Leqembi | $20 |
| Abbvie | Meals · 2025-04-11 | Ubrelvy | $5 |
| Abbvie | Meals · 2025-04-08 | Botox | $34 |
| Argenx US | Meals · 2025-04-05 | Vyvgart | $29 |
| Argenx US | Meals · 2025-04-04 | Vyvgart | $1 |
| Neuropace | Meals · 2025-04-04 | Rns Neurostimulator Kit | $14 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-03 | Hyqvia | $21 |
| Abbvie | Meals · 2025-04-02 | Qulipta | $28 |
| Alexion Pharmaceuticals | Meals · 2025-04-02 | Ultomiris | $32 |
| Ucb | Meals · 2025-04-02 | Rystiggo | $33 |
| Jazz Pharmaceuticals | Meals · 2025-04-01 | Epidiolex | $33 |
| Neurocrine BioSciences | Meals · 2025-04-01 | Ingrezza | $31 |
| Eisai | Meals · 2025-03-30 | Leqembi | $22 |
| Abbvie | Meals · 2025-03-28 | Ubrelvy | $8 |
| Biogen | Meals · 2025-03-28 | Leqembi | $12 |
| Neurelis | Meals · 2025-03-20 | Valtoco | $21 |
| Abbvie | Meals · 2025-03-19 | Botox | $29 |
| Amgen | Meals · 2025-03-19 | Uplizna | $18 |
| Novartis Pharmaceuticals | Meals · 2025-03-18 | Kesimpta | $19 |
| Abbvie | Meals · 2025-03-18 | Vyalev | $20 |
| Abbvie | Paid to speak or teach · 2025-03-18 | Qulipta | $3,250 |
| Neurocrine BioSciences | Meals · 2025-03-14 | Ingrezza | $13 |
| Neurocrine BioSciences | Meals · 2025-03-14 | Ingrezza | $9 |
| Neurocrine BioSciences | Meals · 2025-03-14 | Ingrezza | $5 |
| Genentech USA | Meals · 2025-03-13 | Ocrevus Zunovo | $25 |
| Merz Pharmaceuticals | Meals · 2025-03-13 | Xeomin | $32 |
| Abbvie | Meals · 2025-03-12 | Ubrelvy | $6 |
| Biogen | Meals · 2025-03-12 | Leqembi | $25 |
| MDD US Operations | Meals · 2025-03-11 | Gocovri | $31 |
| Teva Pharmaceuticals USA | Meals · 2025-03-11 | Austedo Xr | $16 |
| Pfizer | Meals · 2025-03-08 | Nurtec Odt | $21 |
| Abbvie | Meals · 2025-03-07 | None | $25 |
| Abbvie | Meals · 2025-03-07 | None | $70 |
| Abbvie | Meals · 2025-03-07 | None | $25 |
| Abbvie | Travel · 2025-03-07 | None | $724 |
| Abbvie | Meals · 2025-03-07 | None | $57 |
| Abbvie | Travel · 2025-03-06 | None | $181 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-04 | Trintellix | $11 |
| Jazz Pharmaceuticals | Meals · 2025-03-04 | Epidiolex | $23 |
| Ipsen Innovation | Travel · 2025-03-03 | None | $128 |
| Ipsen Innovation | Meals · 2025-02-28 | None | $96 |
| Ipsen Innovation | Travel · 2025-02-28 | None | $247 |
| Ipsen Innovation | Travel · 2025-02-28 | None | $417 |
| Abbvie | Meals · 2025-02-27 | Botox | $23 |
| ANI Pharmaceuticals | Meals · 2025-02-27 | Purified Cortrophin Gel | $25 |
| EMD Serono | Meals · 2025-02-26 | None | $31 |
| Novartis Pharmaceuticals | Meals · 2025-02-25 | Kesimpta | $12 |
| Abbvie | Meals · 2025-02-25 | Vyalev | $19 |
| Abbvie | Meals · 2025-02-25 | Ubrelvy | $6 |
| Abbvie | Meals · 2025-02-25 | Qulipta | $125 |
| Biogen | Meals · 2025-02-25 | Tysabri | $18 |
| Eisai | Meals · 2025-02-25 | Leqembi | $15 |
| Vanda Pharmaceuticals | Meals · 2025-02-24 | Ponvory | $21 |
| Eisai | Paid to speak or teach · 2025-02-21 | Leqembi | $1,170 |
| Biogen | Meals · 2025-02-20 | Leqembi | $20 |
| Ge Healthcare | Meals · 2025-02-20 | None | $24 |
| Alexion Pharmaceuticals | Meals · 2025-02-19 | Ultomiris | $29 |
| Neurocrine BioSciences | Meals · 2025-02-19 | Ingrezza | $8 |
| Mallinckrodt Hospital Products | Meals · 2025-02-18 | Acthar | $19 |
| Octapharma USA | Meals · 2025-02-18 | Panzyga | $15 |
| Octapharma USA | Meals · 2025-02-18 | Panzyga | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-02-18 | Austedo Xr | $8 |
| Ucb | Meals · 2025-02-12 | Nayzilam | $22 |
| Biogen | Meals · 2025-02-11 | Vumerity | $16 |
| Pfizer | Meals · 2025-02-11 | Nurtec Odt | $24 |
| Neurocrine BioSciences | Meals · 2025-02-11 | Ingrezza | $14 |
| TG Therapeutics | Meals · 2025-02-10 | Briumvi | $22 |
| ANI Pharmaceuticals | Meals · 2025-02-10 | Purified Cortrophin Gel | $10 |
| Virtus Pharmaceuticals | Meals · 2025-02-06 | Levorphanol Tartrate | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-06 | Hyqvia | $20 |
| Neurocrine BioSciences | Meals · 2025-02-06 | Ingrezza | $6 |
| Neurelis | Meals · 2025-02-05 | Valtoco | $21 |
| Neurocrine BioSciences | Meals · 2025-02-05 | Ingrezza | $10 |
| ACADIA Pharmaceuticals | Meals · 2025-02-04 | Nuplazid | $16 |
| Lundbeck | Meals · 2025-02-04 | Vyepti | $26 |
| SK Life Science | Meals · 2025-02-04 | None | $58 |
| Amneal Pharmaceuticals | Meals · 2025-02-03 | Crexont | $14 |
| Teva Pharmaceuticals USA | Meals · 2025-02-03 | Austedo Xr | $26 |
| Novartis Pharmaceuticals | Meals · 2025-01-30 | Kesimpta | $2 |
| Novartis Pharmaceuticals | Meals · 2025-01-30 | Kesimpta | $34 |
| MDD US Operations | Meals · 2025-01-29 | Gocovri | $27 |
| Mallinckrodt Hospital Products | Meals · 2025-01-28 | Acthar | $15 |
| ANI Pharmaceuticals | Meals · 2025-01-16 | Purified Cortrophin Gel | $15 |
| Amgen | Meals · 2025-01-15 | Uplizna | $22 |
| Abbvie | Meals · 2025-01-13 | Ubrelvy | $8 |
| Biogen | Meals · 2025-01-10 | Vumerity | $22 |
| Abbvie | Meals · 2025-01-09 | Botox | $20 |
| Alexion Pharmaceuticals | Meals · 2025-01-09 | Ultomiris | $33 |
| Amneal Pharmaceuticals | Meals · 2025-01-09 | Ongentys | $125 |
| Neurocrine BioSciences | Meals · 2025-01-08 | Ingrezza | $20 |
| Neurocrine BioSciences | Meals · 2025-01-08 | Ingrezza | $19 |
| Neurocrine BioSciences | Meals · 2025-01-08 | Ingrezza | $11 |
| Abbvie | Meals · 2025-01-07 | Ubrelvy | $12 |
| Neurocrine BioSciences | Meals · 2025-01-07 | Ingrezza | $7 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $77,401
| Eisai | Leqembi | $16,833 | 22 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $16,659 | 18 payments
|
| Lilly USA | Kisunla | $15,843 | 18 payments
|
| Otsuka America Pharmaceutical | Rexulti | $14,554 | 17 payments
|
| Abbvie | Qulipta | $7,142 | 37 payments
|
| Ipsen Innovation | None | $2,155 | 5 payments
|
| MDD US Operations | Gocovri | $613 | 5 payments
|
| Alexion Pharmaceuticals | Ultomiris | $261 | 8 payments
|
| Ucb | Fintepla | $253 | 13 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $250 | 14 payments
|
| SK Life Science | Xcopri | $246 | 16 payments
|
| Neurocrine Biosciences | Ingrezza | $225 | 9 payments
|
| Octapharma USA | Panzyga | $173 | 9 payments
|
| Genentech USA | Ocrevus | $171 | 10 payments
|
| Harmony Biosciences | Wakix | $166 | 10 payments
|
| Argenx US | Vyvgart Hytrulo | $159 | 9 payments
|
| Neurelis | Valtoco | $153 | 7 payments
|
| EMD Serono | None | $151 | 5 payments
|
| Novartis Pharmaceuticals | Kesimpta | $140 | 9 payments
|
| Biogen | Tysabri | $111 | 5 payments
|
| Lundbeck | Vyepti | $95 | 4 payments
|
| Amneal Pharmaceuticals | Rytary | $91 | 4 payments
|
| Catalyst Pharmaceuticals | Fycompa | $87 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $84 | 4 payments
|
| Neuropace | Rns Neurostimulator Kit | $81 | 4 payments
|
| Amgen | Uplizna | $66 | 3 payments
|
| Pfizer | Nurtec Odt | $65 | 4 payments
|
| CSL Behring | Hizentra | $59 | 3 payments
|
| Vanda Pharmaceuticals | Ponvory | $57 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $46 | 2 payments
|
| Scilex Pharmaceuticals | Elyxyb - Celecoxib | $45 | 2 payments
|
| Ipsen Biopharmaceuticals | Sohonos | $42 | 2 payments
|
| Merz Pharmaceuticals | Xeomin | $41 | 2 payments
|
| TG Therapeutics | Briumvi | $38 | 2 payments
|
| Celgene | Zeposia | $36 | 2 payments
|
| Azurity Pharmaceuticals | Horizant | $36 | 2 payments
|
| Sumitomo Pharma America | Aptiom | $35 | 2 payments
|
| LivaNova USA | Vns Therapy Sentiva Model 1000 Generator | $24 | 1 payment
|
| Ge Healthcare | None | $21 | 1 payment
|
| Jazz Pharmaceuticals | Epidiolex | $18 | 1 payment
|
| Abbott Laboratories | Proclaim | $17 | 1 payment
|
| Averitas Pharma | Qutenza | $16 | 1 payment
|
| Kyowa Kirin | Nourianz | $16 | 1 payment
|
| Banner Life Sciences | Bafiertam | $14 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $14 | 1 payment
|
2023: $29,586
| AbbVie | Qulipta | $11,802 | 30 payments
|
| Otsuka America Pharmaceutical | Rexulti | $10,627 | 18 payments
|
| Ucb | Briviact | $1,625 | 18 payments
|
| MDD US Operations | Myobloc | $1,156 | 7 payments
|
| SK Life Science | Xcopri | $437 | 40 payments
|
| Biogen | Tysabri | $436 | 15 payments
|
| Neurocrine Biosciences | Ingrezza | $342 | 13 payments
|
| Alexion Pharmaceuticals | Ultomiris | $292 | 8 payments
|
| EMD Serono | Mavenclad | $227 | 8 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $225 | 13 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $178 | 3 payments
|
| Argenx US | Vyvgart Hytrulo | $155 | 7 payments
|
| Boston Scientific | None | $146 | 2 payments
|
| Abbott Laboratories | Amplatzer Talisman | $144 | 2 payments
|
| Novartis Pharmaceuticals | Kesimpta | $128 | 10 payments
|
| Amneal Pharmaceuticals | Rytary | $122 | 6 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $108 | 5 payments
|
| Banner Life Sciences | Bafiertam | $104 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Gammagard | $100 | 4 payments
|
| Sumitomo Pharma America | Aptiom | $99 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $91 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $87 | 6 payments
|
| Horizon Therapeutics plc | Uplizna | $80 | 4 payments
|
| Genentech USA | Ocrevus | $75 | 3 payments
|
| Eisai | Leqembi | $71 | 3 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $63 | 1 payment
|
| Pfizer | Comirnaty | $62 | 4 payments
|
| Catalyst Pharmaceuticals | Firdapse | $57 | 3 payments
|
| Lundbeck | Vyepti | $53 | 2 payments
|
| GE HealthCare | None | $50 | 5 payments
|
| Impel Pharmaceuticals | Trudhesa | $44 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | None | $43 | 1 payment
|
| Kyowa Kirin | Nourianz | $42 | 2 payments
|
| Octapharma USA | Panzyga | $42 | 2 payments
|
| CSL Behring | Hizentra | $33 | 2 payments
|
| Lilly USA | Amyvid | $26 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido | $25 | 1 payment
|
| Ipsen Biopharmaceuticals | Dysport | $24 | 1 payment
|
| Celgene | Zeposia | $23 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $23 | 1 payment
|
| Neurelis | Valtoco | $22 | 1 payment
|
| Nevro | Senza | $22 | 1 payment
|
| Upsher-Smith Laboratories | Zembrace Symtouch | $20 | 1 payment
|
| Harmony Biosciences | Wakix | $19 | 1 payment
|
| Virtus Pharmaceuticals | Levorphanol Tartrate | $17 | 1 payment
|
| Acorda Therapeutics | Inbrija | $17 | 1 payment
|
2022: $22,569
| SK Life Science | Xcopri | $9,632 | 23 payments
|
| Argenx US | Vyvgart | $5,160 | 8 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $2,454 | 12 payments
|
| Boston Scientific | Vercise | $793 | 4 payments
|
| Abbvie | Ubrelvy | $431 | 29 payments
|
| Alexion Pharmaceuticals | Ultomiris | $339 | 13 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $302 | 14 payments
|
| Neurocrine Biosciences | Ongentys | $237 | 10 payments
|
| Biogen | Tysabri | $219 | 12 payments
|
| Ucb | Briviact | $203 | 8 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $199 | 11 payments
|
| Kyowa Kirin | Nourianz | $173 | 8 payments
|
| Janssen Pharmaceuticals | Ponvory | $171 | 12 payments
|
| Teva Pharmaceuticals USA | Austedo | $169 | 4 payments
|
| Allergan | Botox | $157 | 13 payments
|
| EMD Serono | Mavenclad | $156 | 11 payments
|
| Banner Life Sciences | Bafiertam | $144 | 9 payments
|
| Genentech USA | Ocrevus | $139 | 6 payments
|
| Mallinckrodt Hospital Products | Acthar | $135 | 8 payments
|
| Eisai | Fycompa | $130 | 6 payments
|
| Medtronic | Synchromedii | $98 | 1 payment
|
| Celgene | Zeposia | $96 | 5 payments
|
| Lundbeck | Vyepti | $87 | 3 payments
|
| Amneal Pharmaceuticals | Rytary | $76 | 5 payments
|
| Novartis Pharmaceuticals | Kesimpta | $68 | 5 payments
|
| Avanir Pharmaceuticals | Nuedexta | $67 | 3 payments
|
| Exeltis USA | Purified Cortrophin Gel | $67 | 4 payments
|
| Lilly USA | Amyvid | $56 | 3 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $52 | 3 payments
|
| GE HealthCare | None | $49 | 3 payments
|
| Acorda Therapeutics | Inbrija | $49 | 2 payments
|
| Genzyme | Aubagio | $45 | 3 payments
|
| CSL Behring | Hizentra | $45 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $38 | 3 payments
|
| Neurelis | Valtoco | $36 | 2 payments
|
| LivaNova USA | Vns Therapy Sentiva Model 1000 Generator | $34 | 2 payments
|
| Axsome Therapeutics | Auvelity | $29 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $28 | 1 payment
|
| Insightec | Exablate | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $24 | 1 payment
|
| Ipsen Biopharmaceuticals | Dysport | $22 | 1 payment
|
| Scilex Pharmaceuticals | None | $17 | 1 payment
|
| Grifols USA | Gamunex-C | $17 | 1 payment
|
| Harmony Biosciences | Wakix | $17 | 1 payment
|
| GRT US Holding | Qutenza | $17 | 1 payment
|
| Horizon Therapeutics plc | Uplizna | $16 | 1 payment
|
| Nevro | Omnia | $15 | 1 payment
|
| Impel Pharmaceuticals | Trudhesa | $14 | 1 payment
|
| Life Molecular Imaging | Neuraceq | $14 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $13 | 1 payment
|
2021: $21,333
| SK Life Science | Xcopri | $8,142 | 15 payments
|
| Allergan | Ubrelvy | $3,424 | 15 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $3,335 | 14 payments
|
| Banner Life Sciences | Bafiertam | $986 | 8 payments
|
| Boston Scientific | General Dbs | $708 | 7 payments
|
| AbbVie | Duopa | $600 | 30 payments
|
| Teva Pharmaceuticals USA | Ajovy | $455 | 18 payments
|
| Biogen | Tysabri | $407 | 16 payments
|
| Novartis Pharmaceuticals | Kesimpta | $301 | 21 payments
|
| EMD Serono | None | $240 | 11 payments
|
| Kyowa Kirin | Nourianz | $207 | 11 payments
|
| Eisai | Fycompa | $201 | 14 payments
|
| Alexion Pharmaceuticals | Soliris | $198 | 14 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $175 | 13 payments
|
| Mallinckrodt Hospital Products | Acthar | $167 | 11 payments
|
| LivaNova USA | Vns - Sentiva | $142 | 8 payments
|
| Ucb | Briviact | $138 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $115 | 7 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $93 | 5 payments
|
| Lundbeck | Vyepti | $92 | 5 payments
|
| Genentech USA | Ocrevus | $85 | 4 payments
|
| Amneal Pharmaceuticals | Rytary | $83 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $77 | 4 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $76 | 4 payments
|
| Merz Pharmaceuticals | Xeomin | $61 | 2 payments
|
| Amgen | Aimovig | $60 | 2 payments
|
| Adamas Pharmaceuticals | Gocovri | $59 | 3 payments
|
| CSL Behring | Hizentra | $56 | 3 payments
|
| Horizon Therapeutics plc | Uplizna | $54 | 3 payments
|
| Celgene | Zeposia | $51 | 3 payments
|
| Genzyme | Aubagio | $51 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $42 | 2 payments
|
| Neurelis | Valtoco | $41 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $39 | 2 payments
|
| Zogenix | Fintepla | $37 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $34 | 2 payments
|
| BioDelivery Sciences International | Belbuca | $33 | 2 payments
|
| Acorda Therapeutics | Inbrija | $27 | 2 payments
|
| Greenwich Biosciences | Epidiolex | $26 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $22 | 1 payment
|
| Merck Sharp & Dohme | Belsomra | $21 | 1 payment
|
| Ge Healthcare | None | $20 | 3 payments
|
| Akcea Therapeutics | Tegsedi | $20 | 1 payment
|
| Catalyst Pharmaceuticals | Firdapse | $19 | 1 payment
|
| Neuropace | Rns System | $18 | 1 payment
|
| Lilly USA | Reyvow | $18 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $18 | 1 payment
|
| Upsher-Smith Laboratories | Tosymra | $16 | 1 payment
|
| Aquestive Therapeutics | Sympazan | $15 | 1 payment
|
| Ipsen Biopharmaceuticals | None | $15 | 1 payment
|
| Pfizer | Reyvow | $14 | 1 payment
|
2020: $28,199
| Allergan | Ubrelvy | $11,431 | 24 payments
|
| SK Life Science | Cenobamate | $9,766 | 29 payments
|
| Acorda Therapeutics | Inbrija | $2,074 | 6 payments
|
| Janssen Pharmaceuticals | None | $1,320 | 1 payment
|
| Banner Life Sciences | Bafiertam | $800 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $300 | 24 payments
|
| Novartis Pharmaceuticals | Mayzent | $288 | 18 payments
|
| Eisai | Fycompa | $210 | 9 payments
|
| Harmony Biosciences | Wakix | $182 | 9 payments
|
| Ucb | Briviact | $167 | 7 payments
|
| Kyowa Kirin | Nourianz | $143 | 10 payments
|
| Alexion Pharmaceuticals | Soliris | $134 | 7 payments
|
| EMD Serono | Mavenclad | $131 | 9 payments
|
| Supernus Pharmaceuticals | Oxtellar Xr | $85 | 5 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $82 | 4 payments
|
| Ge Healthcare | None | $77 | 5 payments
|
| Avanir Pharmaceuticals | Nuedexta | $72 | 3 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $72 | 4 payments
|
| Amneal Pharmaceuticals | Rytary | $69 | 4 payments
|
| Genentech USA | Ocrevus | $65 | 3 payments
|
| Biogen | Tysabri | $58 | 3 payments
|
| LivaNova USA | Vns Therapy | $57 | 3 payments
|
| Amgen | Aimovig | $52 | 2 payments
|
| Upsher-Smith Laboratories | Tosymra Sumatriptan Nasal Spray | $47 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $45 | 3 payments
|
| Arbor Pharmaceuticals | Horizant | $43 | 2 payments
|
| Genzyme | Lemtrada | $42 | 2 payments
|
| Merck Sharp & Dohme | Belsomra | $38 | 2 payments
|
| Lilly USA | Emgality | $32 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $31 | 2 payments
|
| Adamas Pharmaceuticals | Gocovri | $29 | 2 payments
|
| Lundbeck | Northera | $24 | 1 payment
|
| Catalyst Pharmaceuticals | Firdapse | $22 | 1 payment
|
| AbbVie | Duopa | $21 | 1 payment
|
| Alnylam Pharmaceuticals | Givlaari | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $20 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $20 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $19 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $18 | 1 payment
|
| Zyla Life Sciences | Sprix | $17 | 1 payment
|
| IBSA Pharma | Licart | $17 | 1 payment
|
| Celgene | Zeposia | $17 | 1 payment
|
| Horizon Therapeutics plc | Duexis | $14 | 1 payment
|
| CSL Behring | Hizentra | $14 | 1 payment
|
| RedHill Biopharma | Movantik | $13 | 1 payment
|
2019: $17,503
| Acorda Therapeutics | Inbrija | $10,442 | 17 payments
|
| Boston Scientific | General Dbs | $1,818 | 10 payments
|
| LivaNova USA | Vns Therapy | $1,671 | 12 payments
|
| Novartis Pharmaceuticals | Mayzent | $1,228 | 31 payments
|
| Alexion Pharmaceuticals | Soliris | $259 | 21 payments
|
| Genzyme | Lemtrada | $255 | 8 payments
|
| Ucb | Briviact | $208 | 9 payments
|
| Teva Pharmaceuticals USA | Ajovy | $205 | 18 payments
|
| Genentech USA | Ocrevus | $167 | 10 payments
|
| Ipsen Biopharmaceuticals | Dysport | $127 | 5 payments
|
| Allergan | Botox | $119 | 11 payments
|
| Biogen | Tysabri | $78 | 4 payments
|
| Sunovion Pharmaceuticals | Aptiom | $72 | 7 payments
|
| Amneal Pharmaceuticals | Rytary | $67 | 5 payments
|
| Avanir Pharmaceuticals | Nuedexta | $60 | 3 payments
|
| CSL Behring | Hizentra | $59 | 3 payments
|
| Eisai | Fycompa | $52 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $52 | 3 payments
|
| Lilly USA | Emgality | $50 | 3 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $49 | 3 payments
|
| Lundbeck | Northera | $47 | 2 payments
|
| Kyowa Kirin | Nourianz | $43 | 2 payments
|
| Adamas Pharmaceuticals | Gocovri | $37 | 2 payments
|
| Merz North America | Xeomin | $33 | 1 payment
|
| Amgen | Aimovig | $29 | 1 payment
|
| Mallinckrodt Enterprises | Acthar | $25 | 1 payment
|
| AbbVie | Duopa | $22 | 1 payment
|
| Vertical Pharmaceuticals | Osmolex Er | $21 | 1 payment
|
| Catalyst Pharmaceuticals | Firdapse | $21 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $20 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $19 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $18 | 1 payment
|
| EMD Serono | Mavenclad | $18 | 1 payment
|
| Ge Healthcare | None | $17 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $16 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $15 | 1 payment
|
| Scilex Pharmaceuticals | Ztlido 30 Pouch in 1 Carton 1 Patch in 1 Pouch | $13 | 1 payment
|
| Pernix Therapeutics Holdings | Zohydro Er | $12 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $11 | 1 payment
|
| Pfizer | Lyrica | $10 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2022 | Their institution | $1,207,090 |
| Eli Lilly and Company · A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer'S Disease (Trailblazer-Alz 2) · 2023 | Their institution | $534,866 |
| Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2019 | Their institution | $393,764 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2021 | Their institution | $372,014 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer'S Disease · 2024 | Their institution | $350,569 |
| Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2020 | Their institution | $306,827 |
| Eli Lilly and Company · A Randomized, Double-Blinded Study To Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer'S Disease · 2025 | Their institution | $259,077 |
| Eli Lilly and Company · A Study of Remternetug Versus Placebo in Early Alzheimer'S Disease Participants at Risk for Cognitive and Functional Decline · 2025 | Their institution | $228,159 |
| Biogen, Inc. · A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Verify the Clinical Benefit of Aducanumab (Biib037) in Participants With Alzheimer'S Disease · 2023 | Their institution | $198,808 |
| Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2021 | Their institution | $155,131 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2024 | Their institution | $149,547 |
| Eli Lilly and Company · A Master Protocol To Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) · 2025 | Their institution | $133,050 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimers Disease (Ad), Followed By An Open-Label Extensio · 2022 | Their institution | $130,184 |
| Novartis Pharmaceuticals Corporation · Exploring the Safety and Tolerability of Conversion To Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded · 2020 | Their institution | $124,932 |
| Novartis Pharmaceuticals Corporation · Exploring the Safety and Tolerability of Conversion To Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded · 2019 | Their institution | $121,883 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy · 2025 | Their institution | $116,355 |
| Eli Lilly and Company · A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating Ly3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy · 2025 | Their institution | $114,794 |
| Ipsen Innovation · A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation and Dose Finding Phase II Study To Evaluate the Safety and Efficacy of Ipn10200 in the Prevention of Episodic Or Chronic Migraine in Adults · 2025 | Their institution | $113,274 |
| Eli Lilly and Company · Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer'S Disease · 2023 | Their institution | $111,233 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer'S Disease · 2025 | Their institution | $96,483 |
| UCB SA · A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinsons Disease · 2022 | Their institution | $95,319 |
| Novartis Pharmaceuticals Corporation · Exploring the Safety and Tolerability of Conversion To Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded · 2021 | Their institution | $84,855 |
| UCB SA · A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinson'S Disease · 2023 | Their institution | $84,521 |
| ABBVIE INC. · A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of Abbv-951 To Oral Carbidopa/Levodopa in Advanced Parkinsons Disease Patients · 2021 | Their institution | $78,252 |
| Sage Therapeutics, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Effects of Sage-718 in Parkinson'S Disease Cognitive Impairment · 2024 | Their institution | $74,597 |
| Allergan Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine · 2019 | Their institution | $73,919 |
| UCB SA · A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinson’S Disease · 2024 | Their institution | $72,620 |
| Adamas Pharmaceuticals, Inc. · A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study To Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment · 2019 | Their institution | $71,981 |
| ABBVIE INC. · Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinson Disease · 2025 | Their institution | $66,844 |
| Biogen, Inc. · A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Verify the Clinical Benefit of Aducanumab (Biib037) in Participants With Alzheimer'S Disease · 2024 | Their institution | $59,383 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimer'S Disease (Ad), Followed By An Open-Label Extension Period · 2023 | Their institution | $59,106 |
| UCB SA · A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinsons Disease · 2025 | Their institution | $57,973 |
| Eli Lilly and Company · A Randomized, Double-Blind, Phase 3 Study To Investigate the Efficacy and Safety of Ly3437943 Once Weekly Compared To Placebo in Participants With Severe Obesity and Established Cardiovascular Disease · 2025 | Their institution | $57,023 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer'S Disease · 2022 | Their institution | $53,589 |
| Sunovion Pharmaceuticals Inc. · Study of Modified Stem Cells (Sb623) in Patients With Chronic Motor Deficit From Ischemic Stroke (Actissima) · 2019 | Their institution | $52,273 |
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2023 | Their institution | $52,022 |
| UCB SA · A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinson’S Disease · 2024 | Their institution | $51,306 |
| Eli Lilly and Company · A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating Ly3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy · 2024 | Their institution | $47,575 |
| Sage Therapeutics, Inc. · A Phase 2, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 Monotherapy and Adjunctive Therapy With Propranolol in the Treatment of Individuals With Essential Tremor · 2020 | Their institution | $44,327 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy · 2025 | Their institution | $40,795 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type · 2021 | Their institution | $39,973 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee · 2019 | Their institution | $39,204 |
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2022 | Their institution | $35,562 |
| Osmotica Pharmaceutical Corp. · An Open-Label Study To Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity · 2020 | Their institution | $35,350 |
| Lexicon Pharmaceuticals, Inc. · 2024 | Their institution | $33,243 |
| UCB SA · A Dose-Blinded Extension Study To Evaluate the Long-Term Efficacy, Safety, and Tolerability of Ucb0599 in Study Participants With Parkinson’S Disease · 2024 | Their institution | $30,634 |
| Lexicon Pharmaceuticals, Inc. · Lx9211.1-204-Dpn · 2025 | Their institution | $30,026 |
| SK Life Science, Inc. · Xcopri · 2021 | Their institution | $29,162 |
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2024 | Their institution | $28,836 |
| SK Life Science, Inc. · Cenobamate · 2020 | Their institution | $28,348 |
| ABBVIE INC. · Open-Label Trial in Parkinson S Disease (Pd) (Tempo-4) · 2025 | Their institution | $27,781 |
| UCB SA · A Dose-Blinded Extension Study To Evaluate the Long-Term Efficacy, Safety, and Tolerability of Ucb0599 in Study Participants With Parkinsons Disease · 2025 | Their institution | $27,105 |
| PFIZER INC. · A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain · 2019 | Their institution | $25,132 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $25,095 |
| ABBVIE INC. · An Open-Label Extension of Studies M15-736 and M20-339 To Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of Abbv-951 in Subjects With Advanced Parkinsons Disease · 2021 | Their institution | $24,872 |
| Allergan, Inc. · A Phase 3, Multicenter, Open-Label 40-Week Extension Study To Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine · 2020 | Their institution | $24,167 |
| ABBVIE INC. · Flexible-Dose Trial in Early Parkinson S Disease (Pd) (Tempo-2) · 2025 | Their institution | $23,864 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type · 2022 | Their institution | $23,356 |
| ABBVIE INC. · Study Comparing Continuous Subcutaneous Infusion of Abbv-951 With Oral Carbidopa/Levodopa Tablets for Treatment of Motor Fluctuations in Adult Participants With Advanced Parkinsons Disease · 2021 | Their institution | $21,387 |
| ABBVIE INC. · Study of Intramuscular Injections of Abbv-950 To Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity · 2024 | Their institution | $21,043 |
| H. Lundbeck A S · A Trial of Eptinezumab in Participants With Migraine and Insufficient Response To Anti-Cgrp Medications · 2025 | Their institution | $20,405 |
| Eli Lilly and Company · Assessment of Safety Tolerability and Efficacy of Ly3372689 in Early Symptomatic Alzheimer'S Disease · 2023 | Their institution | $20,159 |
| ABBVIE INC. · Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinsonx27s Disease · 2022 | Their institution | $19,904 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimer’S Disease (Ad), Followed By An Open-Label Extension Period · 2024 | Their institution | $19,161 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $19,109 |
| Osmotica Pharmaceutical Corp. · An Open-Label Study To Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity · 2019 | Their institution | $18,968 |
| UCB SA · A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinsons Disease · 2025 | Their institution | $18,220 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Study To Evaluate the Efficacy and Safety of Vx-150 in Treating Subjects With Pain Caused By Small Fiber Neuropathy · 2019 | Their institution | $17,436 |
| ACADIA Pharmaceuticals Inc · Nuplazid · 2019 | Their institution | $17,240 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2022 | Their institution | $16,591 |
| Biogen, Inc. · A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Verify the Clinical Benefit of Aducanumab (Biib037) in Participants With Alzheimer'S Disease · 2022 | Their institution | $16,078 |
| Osmotica Pharmaceutical Corp. · A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study To Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis · 2019 | Their institution | $16,077 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $15,892 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Ly3314814 in Mild Alzheimers Disease Dementia · 2019 | Their institution | $15,169 |
| Allergan Inc. · A Phase 3, Multicenter, Open-Label 40-Week Extension Study To Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine · 2019 | Their institution | $14,932 |
| Celgene Corporation · Phiii Efficacy and Safety of Rpc1063 in Relapsing Ms (Rpc01-3001) · 2020 | Their institution | $14,904 |
| Allergan, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine · 2020 | Their institution | $14,479 |
| Eli Lilly and Company · A Master Protocol To Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) · 2024 | Their institution | $14,402 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimers Disease (Ad), Followed By An Open-Label Extensio · 2021 | Their institution | $14,232 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2025 | Their institution | $14,230 |
| Ipsen Pharma SAS · A Multicentre, Interventional, Post-Marketing, Randomised, Double-Blind, Crossover Study To Evaluate the Clinical Safety and Efficacy of Abobotulinumtoxina (Dysport) in Comparison With Onabotulinumtoxina (Botox) When Treating Adults With Upper Limb Spasticity · 2025 | Their institution | $14,198 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2025 | Their institution | $13,778 |
| UCB SA · A Dose-Blinded Extension Study To Evaluate the Long-Term Efficacy, Safety, and Tolerability of Ucb0599 in Study Participants With Parkinson'S Disease · 2023 | Their institution | $13,707 |
| ABBVIE INC. · Study of Oral Atogepant When Added To Onabotulinumtoxina (Botox) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine · 2022 | Their institution | $13,593 |
| ABBVIE INC. · Study of Oral Ubrogepant To Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine · 2024 | Their institution | $13,250 |
| Ipsen Pharma SAS · A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab As First-Line Treatment of Advanced Renal Cell Carcinoma in Adults · 2023 | Their institution | $13,087 |
| Adamas Pharmaceuticals, Inc. · A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment · 2020 | Their institution | $12,844 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2025 | Their institution | $12,802 |
| ABBVIE INC. · Study of Botox Injections in Prevention of Migraine in Adult Participants With Episodic Migraine · 2023 | Their institution | $12,449 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimers Disease (Ad), Followed By An Open-Label Extension Period · 2025 | Their institution | $12,445 |
| Biohaven Pharmaceuticals, Inc. · Phase 3 Multicenter Randomized Double-Blindgroup Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents ? 6 To <18 Years of Age · 2021 | Their institution | $12,445 |
| ABBVIE INC. · M23-499 Ph 2 Spasticity · 2024 | Their institution | $12,182 |
| ABBVIE INC. · Study of Botox Injections in Prevention of Migraine in Adult Participants With Episodic Migraine · 2022 | Their institution | $12,096 |
| ABBVIE INC. · M23-712 - A Study of Oral Atogepant Tablets To Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 To 17 Years · 2025 | Their institution | $12,052 |
| Janssen Research & Development, LLC · Multicenter, Randomized, Double-Blind, Parallel-Group, Add-on, Superiority Study To Compare the Efficacy and Safety of Ponesimod To Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera) · 2020 | Their institution | $11,936 |
| SK Life Science, Inc. · An Open Label, Multicenter, Safety and Pharmacokinetic Study of Ykp3089 As Adjunctive Therapy in Subjects With Partial Onset Seizures · 2020 | Their institution | $10,737 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2024 | Their institution | $10,017 |
| ABBVIE INC. · Agn-151607-Dp for the Preventive Treatment of Chronic Migraine in Adults: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study (the Pursue Study) · 2024 | Their institution | $9,825 |
| ABBVIE INC. · Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinson Disease · 2024 | Their institution | $9,797 |
| UCB SA · A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinsons Disease · 2021 | Their institution | $9,734 |
| ABBVIE INC. · Study of Intramuscular Injections of Abbv-950 To Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity · 2023 | Their institution | $9,316 |
| ABBVIE INC. · Study of Oral Atogepant When Added To Onabotulinumtoxina (Botox) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine · 2024 | Their institution | $9,270 |
| ACADIA Pharmaceuticals Inc · 2024 | Their institution | $9,198 |
| Janssen Research & Development, LLC · Ms Phase 3 Add on Hq - Ac-058b302 · 2019 | Their institution | $9,180 |
| ABBVIE INC. · Study of Oral Ubrogepant To Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine · 2025 | Their institution | $9,100 |
| Allergan, Inc. · A Phase 3, Multicenter, Open-Label 40-Week Extension Study To Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine · 2021 | Their institution | $8,995 |
| ABBVIE INC. · Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinsons Disease · 2023 | Their institution | $8,588 |
| ABBVIE INC. · Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson S Disease With Motor Fluctuations (Tempo-3) · 2025 | Their institution | $8,565 |
| Biogen, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess the Safety, Tolerability, and Efficacy of Biib092 in Subjects With Mild Cognitive Impairment Due To Alzheimer'S Disease Or With Mild Alzheimer'S Disease · 2022 | Their institution | $8,378 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A 12-Week, Multicenter, Active-Treatment Extension Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer'S Type · 2023 | Their institution | $8,240 |
| SK Life Science, Inc. · Ykp3089c049 · 2024 | Their institution | $7,475 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy · 2024 | Their institution | $7,233 |
| ABBVIE INC. · M22-418 - Study of Oral Atogepant When Added To Onabotulinumtoxina (Botox) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine · 2025 | Their institution | $7,149 |
| ABBVIE INC. · A Study of Oral Atogepant Tablets To Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 To 17 Years · 2025 | Their institution | $6,780 |
| Adamas Pharmaceuticals, Inc. · A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study To Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment · 2020 | Their institution | $6,661 |
| Ipsen Pharma SAS · A Double-Blind, Randomized, Placebo-Controlled Study and Open-Label Long Term Extension To Evaluate the Efficacy and Safety of Elafibranor 80 Mg in Patients With Primary Biliary Cholangitis With Inadequate Response Or Intolerance To Ursodeoxycholic Acid · 2024 | Their institution | $6,492 |
| ABBVIE INC. · M23-714 - Study of Oral Ubrogepant To Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine · 2025 | Their institution | $6,476 |
| Adamas Pharmaceuticals, Inc. · A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment · 2021 | Their institution | $6,171 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer'S Disease · 2022 | Their institution | $6,022 |
| Biohaven Pharmaceuticals, Inc. · Phase 3 Multicenter Randomized Double-Blindgroup Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents = 6 To <18 Years of Age · 2021 | Their institution | $5,861 |
| Novartis Pharmaceuticals Corporation · Exploring the Safety and Tolerability of Conversion To Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded · 2022 | Their institution | $5,798 |
| ABBVIE INC. · Study of Oral Atogepant When Added To Onabotulinumtoxina (Botox) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine · 2025 | Their institution | $5,784 |
| ABBVIE INC. · Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinsons Disease · 2022 | Their institution | $5,767 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A 12-Week, Multicenter, Active-Treatment Extension Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer'S Type · 2021 | Their institution | $5,679 |
| Sage Therapeutics, Inc. · A Phase 2, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 Monotherapy and Adjunctive Therapy With Propranolol in the Treatment of Individuals With Essential Tremor · 2021 | Their institution | $5,594 |
| SK Life Science, Inc. · Ykp3089c049 · 2025 | Their institution | $5,557 |
| Biohaven Pharmaceutical Holding Company Ltd. · Phase 3 Multicenter Randomized Double-Blindgroup Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents = 6 To <18 Years of Age · 2022 | Their institution | $5,389 |
| Eli Lilly and Company · A Study of Remternetug Versus Placebo in Early Alzheimer'S Disease Participants at Risk for Cognitive and Functional Decline · 2024 | Their institution | $5,373 |
| H. Lundbeck A S · Cognitive Interview Study To Evaluate Phase 2 Trial Anchors in Patients With Parkinsons Disease · 2025 | Their institution | $5,300 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2021 | Their institution | $5,173 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A 12-Week, Multicenter, Active-Treatment Extension Trial To Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer'S Type · 2022 | Their institution | $5,112 |
| PFIZER INC. · Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study To Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2023 | Their institution | $5,000 |
| ABBVIE INC. · Study of Oral Atogepant When Added To Onabotulinumtoxina (Botox) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine · 2023 | Their institution | $4,997 |
| Adamas Pharmaceuticals, Inc. · A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment · 2019 | Their institution | $4,985 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial To Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type · 2020 | Their institution | $4,833 |
| Celgene Corporation · Phiii Efficacy and Safety of Rpc1063 in Relapsing Ms (Rpc01-3001) (Rpc01-3001) · 2019 | Their institution | $4,553 |
| Sunovion Pharmaceuticals Inc. · A Study of A Drug To Be Used in Addition With Another Drug To Treat Adults With Uncontrolled Partial-Onset Seizures · 2019 | Their institution | $4,396 |
| PFIZER INC. · Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study To Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2024 | Their institution | $4,346 |
| ABBVIE INC. · M22-418 Atogepant-Botox Combination Study · 2024 | Their institution | $3,708 |
| Alexion Pharmaceuticals, Inc. · An Observational, Non-Interventional, Long-Term Registry of Patients With Generalized Myasthenia Gravis Treated With Soliris · 2020 | Their institution | $3,672 |
| Biohaven Pharmaceuticals, Inc. · Phase 3 Multicenter Randomized Double-Blind Group Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents 6 To <18 Years of Age · 2021 | Their institution | $3,549 |
| Novartis Pharmaceuticals Corporation · Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy · 2020 | Their institution | $3,501 |
| ABBVIE INC. · Study of Botox Injections in Prevention of Migraine in Adult Participants With Episodic Migraine · 2025 | Their institution | $3,389 |
| Biohaven Pharmaceutical Holding Company Ltd. · Phase 3 Multicenter Randomized Double-Blind Group Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents ? 6 To <18 Years of Age · 2022 | Their institution | $3,303 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2022 | Their institution | $3,094 |
| Eli Lilly and Company · A Randomized, Double-Blinded Study To Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer'S Disease · 2024 | Their institution | $2,802 |
| ABBVIE INC. · Flexible-Dose Trial in Early Parkinson S Disease (Pd) (Tempo-2) · 2024 | Their institution | $2,795 |
| Sunovion Pharmaceuticals Inc. · A Study of A Drug To Be Used in Addition With Another Drug To Treat Adults With Uncontrolled Partial-Onset Seizures · 2020 | Their institution | $2,716 |
| JAZZ PHARMACEUTICALS INC. · A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of Jzp-110 [(R)-2-Amino-3-Phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson'S Disease and Excessive Sleepiness · 2019 | Their institution | $2,711 |
| ABBVIE INC. · Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson S Disease With Motor Fluctuations (Tempo-3) · 2024 | Their institution | $2,500 |
| Lexicon Pharmaceuticals, Inc. · Lx9211.1-204-Dpn · 2024 | Their institution | $2,500 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2022 | Their institution | $2,435 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer'S Disease · 2022 | This clinician | $2,290 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2025 | Their institution | $1,928 |
| ABBVIE INC. · A Phase 3 Multicenter 24-Week Open-Label Study To Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added To Onabotulinumtoxina (Botox) for the Preventive Treatment of Chronic Migraine · 2025 | Their institution | $1,854 |
| SK Life Science, Inc. · Ykp3089c025 · 2025 | Their institution | $1,850 |
| Sunovion Pharmaceuticals Inc. · A Study To Evaluate the Efficacy, Safety and Tolerability of Sep-363856 in Subjects With Parkinson'S Disease Psychosis · 2020 | Their institution | $1,767 |
| ABBVIE INC. · M20-098 Abbv-951 Apd · 2024 | Their institution | $1,657 |
| Lexicon Pharmaceuticals, Inc. · 2024 | This clinician | $1,622 |
| Eli Lilly and Company · A Randomized, Double-Blind, Phase 3 Study To Investigate the Efficacy and Safety of Ly3437943 Once Weekly Compared To Placebo in Participants With Severe Obesity and Established Cardiovascular Disease · 2024 | Their institution | $1,589 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2022 | This clinician | $1,571 |
| ABBVIE INC. · Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson'S Disease With Motor Fluctuations (Tempo-3) · 2024 | Their institution | $1,542 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $1,440 |
| ABBVIE INC. · 3110-305-002 Ph3 Pivotal Peds Post Approval - Pmr (M21-265) · 2024 | Their institution | $1,440 |
| Novartis Pharmaceuticals Corporation · Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy · 2021 | Their institution | $1,414 |
| ACADIA Pharmaceuticals Inc · 2025 | This clinician | $1,406 |
| Sunovion Pharmaceuticals Inc. · A Study To Evaluate the Efficacy, Safety and Tolerability of Sep-363856 in Subjects With Parkinson'S Disease Psychosis · 2019 | Their institution | $1,319 |
| ABBVIE INC. · School Intervention Program To Promote Healthy Lifestyle Among Male Adolescent Students in King Faisal Residential City, Jeddah, Western Region, 2014-15 · 2024 | Their institution | $1,274 |
| ABBVIE INC. · A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor · 2025 | Their institution | $1,243 |
| Allergan, Inc. · A Phase 3, Multicenter, Open-Label 40-Week Extension Study To Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine · 2020 | Their institution | $1,212 |
| AbbVie Inc. · Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinson'S Disease · 2022 | Their institution | $982 |
| ABBVIE INC. · A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 To 17 Years of Age · 2025 | Their institution | $963 |
| Alexion Pharmaceuticals, Inc. · Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies · 2021 | Their institution | $898 |
| ABBVIE INC. · An Open-Label Extension of Studies M15-736 and M20-339 To Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of Abbv-951 in Subjects With Advanced Parkinson S Disease · 2025 | Their institution | $828 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2023 | Their institution | $826 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $814 |
| Allergan Inc. · A Phase 3, Multicenter, Open-Label 40-Week Extension Study To Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine · 2019 | Their institution | $660 |
| ABBVIE INC. · M23-714 Ubrelvy Menstrual Migraine · 2024 | Their institution | $600 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With An Open-Label Extension · 2025 | Their institution | $600 |
| ABBVIE INC. · A Multicenter, Open-Label, Extension Study To Evaluate the Long-Term Safety and Tolerability of Atogepant in Pediatric Subjects 6 To 17 Years of Age With Migraine · 2025 | Their institution | $582 |
| ABBVIE INC. · M20-098 - Study To Assess Adverse Events and Change in Disease Activity of 24-Hour Continuous Subcutaneous Infusion of Abbv-951 in Adult Participants With Advanced Parkinson Disease · 2025 | Their institution | $573 |
| Novartis Pharmaceuticals Corporation · Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy · 2019 | Their institution | $561 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2024 | Their institution | $551 |
| Alexion Pharmaceuticals, Inc. · Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies · 2022 | Their institution | $550 |
| UCB SA · A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinson · 2020 | Their institution | $529 |
| Eli Lilly and Company · A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer'S Disease (Trailblazer-Alz 2) · 2023 | This clinician | $465 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2021 | This clinician | $445 |
| Alexion Pharmaceuticals, Inc. · Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies · 2024 | Their institution | $424 |
| Alexion Pharmaceuticals, Inc. · Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies · 2023 | Their institution | $406 |
| Ipsen Innovation · A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation and Dose Finding Phase II Study To Evaluate the Safety and Efficacy of Ipn10200 in the Prevention of Episodic Or Chronic Migraine in Adults · 2024 | Their institution | $381 |
| Alexion Pharmaceuticals, Inc. · Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies · 2025 | Their institution | $208 |
| ABBVIE INC. · 58-Week Open-Label Trial of Tavapadon in Parkinson S Disease (Tempo-4 Trial) · 2024 | Their institution | $182 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer'S Disease · 2022 | This clinician | $20 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer'S Disease · 2025 | Their institution | $6 |
| Eli Lilly and Company · Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer'S Disease · 2023 | This clinician | $1 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013002328
- Licence
- CA A61797California A61797: Current · expires 2028-07-31
- Group
- Neuro-Pain Medical Center Inc · Fresno Community Hospital and Medical Center
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A617970
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 736 E Bullard Ave, #101, Fresno, CA, 93710
- NPI first listed
- 2006-10-03
- NPI last updated
- 2009-08-05
This is when the NPI record was last certified, not a medical board exam.